Natural and Induced Tolerogenic Dendritic Cells

Courtney A. Iberg and Daniel Hawiger
J Immunol February 15, 2020, 204 (4) 733-744; DOI: https://doi.org/10.4049/jimmunol.1901121

Abstract

Dendritic cells (DCs) are highly susceptible to extrinsic signals that modify the functions of these crucial APCs. Maturation of DCs induced by diverse proinflammatory conditions promotes immune responses, but certain signals also induce tolerogenic functions in DCs. These “induced tolerogenic DCs” help to moderate immune responses such as those to commensals present at specific anatomical locations. However, also under steady-state conditions, some DCs are characterized by inherent tolerogenic properties. The immunomodulatory mechanisms constitutively present in such “natural tolerogenic DCs” help to promote tolerance to peripheral Ags. By extending tolerance initially established in the thymus, these functions of DCs help to regulate autoimmune and other immune responses. In this review we will discuss the mechanisms and functions of natural and induced tolerogenic DCs and offer further insight into how their possible manipulations may ultimately lead to more precise treatments for various immune-mediated conditions and diseases.

Introduction

Dendritic cells (DCs) are APCs critical for the initiation of T cell immune responses and for the governing of immune tolerance. Together with other types of cells in the thymus, DCs have important roles in mediating central tolerance, combining thymic deletion of self-reactive T cells and a production of thymically derived regulatory T (tTreg) cells in a cumulative process aimed at preventing overt anti-self responses (1). However, because of differing efficiencies of antigenic presentation in the thymus and the periphery, and cross-reactivity of TCRs, the mature peripheral T cell repertoire still contains T cells that may be reactive to self (2, 3). These self-reactive peripheral T cells can then be primed in the periphery, even by low-affinity peptides that are below their original thresholds for negative selection in the thymus (2, 4), ultimately increasing the risk of autoimmune responses against self-antigens (2, 4–7).

The priming of self-reactive peripheral T cells is controlled by tTreg cells (8). However, the functions of tTreg cells may be overwhelmed by specific proinflammatory autoimmune activation; also, in some individuals, the development of tTreg cells may be compromised (2, 4, 9, 10). Various animal models of autoimmune diseases initiated in healthy animals after immunization with specific self-antigens either in the presence of adjuvants or in the context of an introduced infectious agent have demonstrated that specific priming of preexisting self-reactive T cells mediates an autoimmune process (2, 4–7). Therefore, pathways of thymic tolerance need to be extended by the specific mechanisms operating in the peripheral immune system. Particularly, autoimmune responses can be ameliorated or even completely prevented by the Ag-specific, peripherally formed Treg (pTreg) cells that are induced extrathymically by DCs (7, 11).

Dendritic cells in peripheral tolerance

The roles of DCs in peripheral tolerance have been established by multiple lines of independent experimental evidence. The disturbance of tolerance and immune homeostasis caused by the absence of DCs and their subsets was observed in various experimental systems that relied on a specific in vivo killing of DCs expressing diphtheria toxin receptor or diphtheria toxoid A subunit or by other means, such as a chemical depletion of DCs (12–16). These results are in agreement with other early studies that identified the roles of DCs in the induction of peripheral tolerance by employing methods of specific delivery of defined Ags to DCs in vivo, tracking the uptake of proteins to DCs, and the transgenic expression of ectopic Ags as cytosolic proteins in DCs (17–20). The combination of specific Ag-targeting methods with various genetic models of DCs has allowed for further advances in our understanding of the importance of DCs in governing peripheral tolerance, as we also recently discussed in Ref. 11.

The specific functions of DCs depend, in part, on the developmentally determined diversity of DC subsets reviewed extensively by Murphy and colleagues (21) and Merad et al. (22). Both human and murine DCs consist of two main populations, conventional DC (cDC) and plasmacytoid DC (pDC), both of which develop from progenitors in the bone marrow and then differentiate into various subsets present throughout multiple tissues (23, 24). The cDC population can be further divided into the DC1 and DC2 subsets, as defined by the transcription factors required for their development. The DC1 subset, which requires the transcription factors Irf8, Id2, and Batf3 for development, is distinguished by the expression of XCR1 and further characterized by the expression of additional cell surface molecules, including B and T lymphocyte associated (BTLA), CD8α, and DEC-205. In contrast, the development of DC2s is governed by the transcription factors Irf4 and Notch2, and these DCs are distinguished by cell surface expression of CD172a (SIRPα) as well as DCIR2 and CD11b (11, 23, 24). Although not a main focus of this review, pDCs, characterized by the expression of cell surface molecules (including B220, bone marrow stromal Ag 2 [BST2], and Siglec-H), are primarily involved in antiviral responses but also have some roles in tolerance (11, 25). Importantly, CD141+ (BDCA-3+) XCR1+ BTLA+ human DC1s and CD1c+ CD172a+ CD11b+ human DC2s share many developmental, phenotypical, and functional similarities with their murine counterparts (21, 26).

In addition to their roles in tolerance, DCs have crucial functions in the initiation of immune responses. The efficient priming of immune responses by specific DC subsets requires additional signals from the proinflammatory environment that can be sensed through specific pattern recognition receptors (PRRs) (27–29). These signals lead to the DC acquisition of enhanced properties to induce immune responses in a process referred to as maturation. Overall, the model of such proimmunogenic DC maturation postulates increased proinflammatory cytokine production and increased cell surface expression of costimulatory and MHC molecules and chemokine ligands or receptors in response to microbial and other proinflammatory stimulation (28, 30). In addition to this maturation process resulting in increased immune responses, specific extrinsic signals were also proposed to induce tolerogenic differentiation of DCs. The experiments using bone marrow–derived DCs (BMDCs), monocyte-derived DCs (moDCs), and DCs obtained ex vivo showed that some PRR agonists, as well as various other physiological and pharmaceutical agents, can allow for the induction of DCs with tolerogenic functions. Further, the experiments in vivo revealed that, in response to certain signals in specific anatomical sites (including the intestines and airways), some DCs help to maintain immune homeostasis toward commensal organisms and other Ags, even under partially proimmunogenic conditions (28, 31–33). We propose to refer to such DCs that acquire tolerogenic properties either in vitro or in vivo as “induced tolerogenic DCs” (itDCs), as partially based on the terminology first introduced by Maldonado and von Andrian (34).

However, even in the absence of specific extrinsic signals, generally referred to as steady-state conditions, many DCs that are present in the spleen and other lymphoid organs do not necessarily remain as “immature” immunological bystanders but instead have important roles in initiating and maintaining tolerance to available peripheral Ags (11). These DCs inherently promote in T cells various mechanisms of tolerance, including T cell anergy, T cell deletion, and a conversion of pTreg cells (11). We therefore propose to refer to such DCs as “natural tolerogenic DCs” (ntDCs) (Fig. 1).

FIGURE 1.
FIGURE 1.

The role of ntDCs and itDCs in extrathymic tolerance. Peripheral tolerance extends tolerance initiated centrally in thymus. The ntDCs and itDCs function to promote the deletion or anergy of self-reactive T cells as well as to induce pTreg cells. ntDCs are generally tissue-resident DCs found in multiple immune organs, including the spleen and LNs (highlighted in blue). itDCs are generally found in various tissues and organs, including the lungs, the intestines, and the skin (highlighted in yellow). In these locations, itDCs are in constant contact with a variety of environmental stimuli provided by commensal and pathogenic organisms.

Establishing peripheral tolerance by natural tolerogenic functions of DCs

The physiological steady state can be defined by the undisturbed expression of cytokines and other molecules contributing to the baseline conditions that, together with stromal cells of the secondary lymphoid tissues, provide a framework for the interactions between DCs and T cells (35, 36). Initially, it was postulated that, in the steady state, DCs remain immature akin to BMDCs or moDCs that are characterized by lower expression of MHC and costimulatory molecules when cultured in the absence of maturation signals (35). However, the available experimental evidence has clearly shown that, even in the steady state, DCs can constitutively initiate active mechanisms of tolerance in T cells, such as the conversion of pTreg cells (7, 11). These general contradictions were recognized early by Lutz and Schuler, who proposed that the division between “immature DCs” and “mature DCs” (as defined by DC phenotypes) did not necessarily correspond with “tolerogenic DCs” and “immunogenic DCs,” respectively. Instead, divisive tolerogenic and immunogenic maturation processes were proposed (31), further supported by the identification of transcriptional determinants of certain tolerogenic and immunogenic maturation states in DCs as well as by the emerging concept of “homeostatic maturation” of DCs under steady-state conditions (37–40). For example, a decrease in E-cadherin–mediated cell–to–cell contact results in specific increases in expression of MHC class II (MHCII) and costimulatory molecules (39). The concept of DC maturation in the steady state was additionally defined by other observations of multiple specific gene expression changes comparable, in scope, to those observed under TLR agonist–mediated maturation (30). This process of maturation under homeostatic conditions has also been proposed to result in functions of DCs necessary to induce active mechanisms of tolerance (38). Although the specific mechanisms governing DC functions in vivo under steady-state conditions following their initial development from the bone marrow precursors are still being uncovered, it is clear that these processes are continuous, and some possibly cell autonomous, resulting in the stable numbers and phenotypes of DCs expressing crucial molecules involved in tolerance (Fig. 2 and as discussed below).

FIGURE 2.
FIGURE 2.

ntDCs promote tolerance in the steady state. Using multiple receptors (examples of which are shown), ntDCs constitutively uptake and process tissue-derived Ags from apoptotic cells for subsequent presentation to T cells, thereby further enhancing tolerance toward self-antigens. Similarly, ntDCs uptake, process, and present soluble Ag. ntDCs, which are predominantly DC1s, inherently express immunomodulatory molecules (including BTLA, PD-L1, B7h, and CD80/CD86) as well as cytokines (such as TGF-β and IL-10). Interaction of BTLA with the T cell–expressed receptor HVEM is necessary for the efficient induction of pTreg cells and long-lasting tolerance.

In the steady state, DCs can induce multiple mechanisms of tolerance in T cells including anergy, but a de novo conversion of pTreg cells bestows a dominant and long-lasting tolerance to peripheral Ags (7, 11, 41–44). Although in the steady state Ags initially acquired by all cDCs can induce tolerance, DC1s are more prone to induce tolerogenic effects as compared with DC2s (7, 11, 42). The specialization among DCs can be attributed to different localization of DCs within a local architecture of immune organs, differences in the efficiencies of processing and presentation of Ags to T cells, and the specific immunomodulatory mechanisms in DC1s and DC2s (11, 45–48). The immunomodulatory pathways are of particular importance in the mediation of a tolerogenic partnership of DCs and T cells (49). Importantly, the engagement of immunomodulatory axes (including programmed death ligand-1 [PD-L1]/programmed death-1 [PD-1], CD80/CD86/CTLA-4, and B7h/ICOS) can promote Foxp3 expression, pTreg cell induction, and tolerance (7, 11, 49). Specifically, the PD-L1/PD-1 axis promotes immune tolerance via PD-L1’s competition with costimulatory CD28 for binding with B7-1 as well as by the recruitment of SHP-2 by PD-1, which negatively impacts TCR signaling (50). Moreover, CTLA-4 (CD152) expressed on the T cell surface competes with the costimulatory molecule CD28 for binding with CD80/CD86 (B7-1 and B7-2) present on the surface of the DC. Although CTLA-4 can remove CD80/CD86 from the DC surface, it also directly negatively regulates CD4+ and CD8+ T cell activation by dampening TCR signaling, hindering IL-2 production, and preventing cell cycle progression (51–53). Finally, B7h (ICOS-L or B7RP-1) is constitutively expressed on DCs, and expression of its receptor, ICOS, is induced upon T cell activation (49). Related to other members of the CD28 Ig superfamily, ICOS (together with its binding partner B7h) has proven important in the development of Treg cells, and a deficiency in ICOS signaling has rendered mice more susceptible to various autoimmune pathologies, although ICOS functions are required for the progression of some autoimmune processes (54–58).

Among various cytokines governing immune responses, the presence of TGF-β is often correlated with maintaining immune homeostasis. The absence of TGF-β leads to spontaneous lymphoproliferation and inflammatory disease, and TGF-β also influences the expression of IL-10, an important protolerogenic cytokine (34, 49, 59, 60). By acting directly on T cells, TGF-β promotes differentiation of both Treg and some effector T cells (43, 61–65). Metabolites, such as retinoic acid (RA), enhance tolerogenic properties of cytokines including TGF-β, further promoting the induction of Foxp3 expression and the amelioration of autoimmune disease (66–70).

In addition to the immunomodulatory pathways described above, which can directly contribute to inducing Foxp3 expression in pTreg cells, recent results identified the roles of BTLA and CD5 in promoting pTreg cell homeostasis via the modulation of the sensitivity of the developing pTreg cells to effector-differentiating cytokines (7, 42, 71, 72). Among the DC populations, BTLA is expressed specifically in DC1s (72). During the interactions between the BTLAhi DC1s and T cells in the steady state, BTLA signals through herpesvirus entry mediator (HVEM) in naive CD4+ T cells to activate MEK and, subsequently, the transcription factor ETS1 to increase expression of Cd5 (42, 72). High CD5 expression then allows for a conversion of these T cells to Foxp3+ pTreg cells by interfering with mammalian target of rapamycin (mTOR) activation in response to effector-differentiating cytokines, such as IL-4, IL-6, and IFN-γ (7, 42, 71).

BTLAhi DC1s reside in lymphoid organs, including the spleen, and these resident lymphoid tissue DCs are ideally positioned to capture systemic self-antigens, including those derived from apoptotic cells (20, 73, 74). Although the specific roles of BTLA in governing tolerance among CD8+ T cells remain unclear, DC1s can maintain tolerance to self-antigens by presenting endogenous Ags to both CD4+ and CD8+ T cells (73, 75). DC1s also have important roles in eliciting Th1 responses as well as in cross-priming CD8+ cytotoxic T cells (23). Such versatile functions of some DC1s may reflect complex mechanisms mediated by BTLA and HVEM (76–79), yet it is also interesting to speculate that at least some of these proimmune functions may be performed by DC1s characterized by low expression of BTLA.

Nevertheless, it is clear that apoptotic materials are an abundant source of tissue self-antigens crucial for the maintenance of immune tolerance (20, 80, 81). The relationship between the uptake, processing, and presentation of apoptotic materials and the functional characteristics of DCs is complex. The phagocytic scavenger receptor CD36 has long been recognized for its role in facilitating the uptake of apoptotic materials via recognition of phosphatidylserine found on the outer leaflets of the membranes of apoptotic cells (74, 82). Consistent with the notion that DC1s are primarily responsible for the constitutive uptake of apoptotic materials, CD36 is expressed highly on DC1s compared with DC2s and pDCs (83, 84). In addition to being a source of Ags, an exposure to apoptotic materials may also enhance the tolerogenic properties of some DCs. An engagement of CD36 can inhibit maturation of moDCs induced by proimmunogenic stimuli and can induce tolerogenic BMDCs that resist LPS stimulation and induce Foxp3+ pTreg cell development (85, 86), also discussed later in the text.

In contrast, necrotic-type materials derived from injured cells can be recognized by Clec9a (DNGR-1), a C-type lectin expressed by some DC1s, resulting in inflammation and maturation of DCs (87, 88). However, under steady-state conditions, the resident lymphoid tissue BTLAhi DC1s (as well as some migratory DCs) exhibit inherent tolerogenic properties (11). The ability of DC1s to uptake, process, and present Ags to T cells in the steady state has been demonstrated by using multiple methods, including a direct targeting of Ags to such DCs by using chimeric Abs specific for DEC-205 and other surface receptors (11, 17, 89). Importantly, the combination of genetic models including a DC-specific deletion of Irf4 (resulting in an increased DC1/DC2 ratio) or a deletion of Batf3 (resulting in decreased numbers of DC1s) and targeted Ag delivery to DC-specific molecules has helped to further clarify the specific functions of DC subsets (11, 17, 42, 49).

In addition to the tolerance promoted by resident lymphoid tissue DCs, tolerance to self-antigens is also promoted by migratory DCs that transport Ags from the nonlymphoid tissue to the lymph nodes (LNs). Such migratory DC1s, especially those found in skin and parenchymal organs, undergo homeostatic maturation in the steady state and have tolerogenic functions (40, 90–92). However, the tolerogenic functions of many migratory DCs are also induced at certain anatomical locations (such as the intestines) upon exposure to specific extrinsic stimuli (as discussed below).

Inducing tolerogenic DCs for the maintenance of homeostasis

In contrast to resident lymphoid tissue DCs and DCs migrating from the parenchymal organs in the steady state, many DCs that are exposed to various environmental stimuli present in the intestines, airways, and skin are constantly at risk for undergoing immunogenic maturation. However, as discussed earlier in the text, these DCs do not induce detrimental immune responses and instead induce tolerogenic functions. The specific tolerogenic mechanisms employed by itDCs remain an area of active investigation, but it is clear that, despite the presence of proinflammatory mediators, these DCs are typically characterized by an elevated production of various anti-inflammatory cytokines and other regulatory molecules (11, 93–99).

Among such specific anatomical sites, the skin represents a crucial barrier that is in constant contact with foreign Ags and commensal microbes and that requires intricately regulated immune responses orchestrated by DCs (93, 100). The lungs are another crucial anatomical site that is continually exposed to commensals and pathogens, therefore also requiring active immunoregulation. Correspondingly, DCs obtained from patients with chronic obstructive pulmonary disease were shown to produce IL-10, leading to the induction of Tr1 regulatory cells (95, 101, 102). The intestines are yet another key organ that remains in constant contact with a large number of commensal bacteria and that can also be exposed to potentially pathogenic microbes. Oral administration of Ags is well established to lead to the induction of Foxp3+ Treg cells, thereby helping to maintain homeostasis (103).

It has recently been suggested that the specific anatomical organization of gut-draining LNs may play a role in the balance of tolerance and immunity, as proximal and distal gut-draining LNs supported primarily tolerogenic and immunogenic responses, respectively (47). In addition to such anatomic specialization, other studies have demonstrated that the presence of commensal microbes from the human gut, dietary metabolites, and some other biologically active molecules results in the formation of itDCs that can differentiate Foxp3+ Treg cells and regulatory Tr1 cells and decrease the numbers of effector T cells (33, 104–107). Accordingly, the pTreg cell–inducing functions of Irf8/Batf3-dependent CD103+CD11b− DC1s help maintain a local immune homeostasis within the gut-associated lymphoid tissues as well as at other mucosal surfaces and also some immune-privileged sites, such as the eye (12, 13, 32, 108–110). Although DC2s are generally less efficient at inducing pTreg cells, some itDC2s in the intestines still promote both Treg cell–independent and Treg cell–dependent tolerance (111, 112).

Recent work identified that stimulation through certain PRRs and the presence of specific cytokines and metabolites can actively divert DCs toward tolerogenic functions [(34, 47, 93, 101, 113) and (Fig. 3)]. In contrast to their proimmunogenic roles, some PRRs may contribute to a tolerogenic sensitization (29, 33, 114–117). However, the impact of individual PRRs on the induction of tolerogenic DCs is likely to be context dependent. For example, BMDCs differentiated in the presence of splenic stroma were found to produce high amounts of IL-10 and dampen naive CD4+ T cell responses in culture (36). Paradoxically, an additional stimulation with TLR-2, -3, -4, and -9 agonists of DCs cocultured with splenic stromal cells further enhances their tolerogenic state, resulting in heightened production and secretion of CXCR3 chemokine IFN-γ–inducible protein 10 (IP-10) and a corresponding decrease in Th1 proliferation (118). Nevertheless, certain TLRs such as TLR-2 appear to be more tolerogenic than other TLRs. In a murine disease model of arthritis, the microbial commensals’ stimulation of TLR-2 on APCs promotes Treg cell suppressive functions and dampens IFN-γ production, whereas stimulation of TLR-4 promotes Th17- and IL-17–driven pathology (119). Various TLRs may also physically associate as heterodimers to promote contrasting responses depending on the specific composition of each heterodimer. Studies using the Yersinia pestis virulence factor LcrV showed that recognition of LcrV by a TLR-2/TLR-6 heterodimer could lead to itDC induction, complete with IL-10 production and Tr1 induction, whereas recognition of LcrV by a TLR-2/TLR-1 heterodimer resulted in IL-12 production and induction of effector Th1 cells (120).

FIGURE 3.
FIGURE 3.

itDCs promote T cell tolerance in response to exogenous signals. itDCs can be induced by multiple types of molecules, including microbial components (which bind to various PRRs, such as TLR-2), pharmacological and dietary agents (such as corticosteroids and probiotics) or certain physiological agents that bind to the AHR or the VDR, and also by other specific metabolites, cytokines, and growth factors. The downstream diverse immunoregulatory effects are mediated by several different signaling pathways, including NF-κB, Wnt/β-catenin, and mTOR, ultimately resulting in active mechanisms of tolerance that induce the expression and production of multiple immunomodulatory mediators, including IL-10, RA, and kynurenine (Kyn) (a metabolic product of tryptophan catabolism that is mediated by IDO1).

A particular agonist may also lead to divergent immune responses by stimulating different PRRs. Early reports suggested that zymosan, a glucan derived from yeast cell walls, promotes IL-10 production and tolerance by concomitant engagement of TLR-2 and dectin-1 (121). However, later reports from ex vivo and in vivo experimental systems suggested that divergent responses may arise from zymosan’s stimulation of these PRRs. It was found that TLR-2 ligation by zymosan increases the expression of Raldh2 by DCs, leading to the production of RA and the eventual promotion of Treg cells via the suppression of effector differentiation. In contrast, ligation of dectin-1 increases Th1 and Th17 differentiation and exacerbates autoimmunity (116). In some instances, the concomitant signaling of specific combinations of other PRRs (such as TLR-2 and TLR-4 or TLR-3, -4, or -5 and DC-SIGN) may result in tolerogenic profiles, including increased IL-10 production and lower costimulatory molecule expression by DCs (122, 123).

In addition to TLRs, signaling via G-protein–coupled receptors (such as GPR109a and GPR81) extends DC-mediated tolerance in the gut. The G-protein–coupled receptor GPR109a is a receptor for commensal bacteria–produced butyrate and niacin that induce production of IL-10 and Aldh1a1 in DCs (124). The deficiency of GPR109a (genetically modeled in Niacr1−/− mice) results in an increased susceptibility to colonic inflammation and colon cancer in azoxymethane- and dextran sulfate sodium–treated mice, respectively (124). Similarly, the G-protein–coupled receptor GPR81 is expressed in intestinal DCs and macrophages and has been shown to be activated by lactate, a product of microbial fermentation that is present in abundance in the colon (125, 126). The genetic deletion of GPR81 results in a decrease in tolerance protecting from colitis, as evidenced by an increase in proinflammatory cytokine production, a decrease in regulatory factors such as IL-10, and a decrease in IDO1 expression; correspondingly, pharmacological activation of GPR81 has been shown to lessen murine colitis severity (126). Also, other molecules, such as DC-SIGN, play a specific role in itDC induction, as well as in the induction of tolerogenic functions in macrophages, by promoting specific mechanisms of tolerance (such as the production of IL-10) in response to various microorganisms (117, 127, 128). However, the binding of DC-SIGN (possibly in concert with the binding of TLRs) to various ligands, including cell wall components and modified oligosaccharides derived from bacterial LPS, results in divergent tolerogenic or immunogenic DC–mediated immune responses and may also lead to Th1 responses (122, 129–131).

Certain cytokines and metabolites have crucial roles in inducing and governing the functions of itDCs as well as in shaping the responses of DCs to PRR ligands. For example, the addition of IL-10 to human DC cultures may lead to decreased expression of MHCII (HLA-DR) and costimulatory molecules, resulting in T cell anergy (132, 133). In the small intestine, RA is locally found at high concentrations due to the metabolism of dietary vitamin A (109, 134). This localized presence of RA then promotes the expression of Raldh2 and production of additional RA by CD103+ DCs in the lamina propria, ultimately resulting in the increased induction of IL-10–producing Foxp3+ Treg cells (as well as in the inhibition of TGF-β–mediated Th17 cell induction and in the imprinting of gut-homing receptors on T cells) (66, 108, 109, 135–137). Consistent with its protolerogenic roles, IL-10 can then downregulate DC expression of MHCII and costimulatory molecules and reverse the effects of proinflammatory cytokines, such as IL-6 and TNF-α (60). Further, IL-10 treatment of human DCs upregulates TLR-2 expression in response to LPS administration, consistent with the protolerogenic functions observed following TLR-2 activation (as discussed above). Such treated DCs also decrease expression of IL-12–related cytokines, possibly further indicating collaborative roles of IL-10 and TLR-2 in the dampening of the immune response (138).

In addition to IL-10, the IL-12 cytokine family member IL-35, predominantly produced by Treg cells, was proposed to dampen T cell responses (139). Similarly, IL-37 decreases the production of proinflammatory cytokines induced by LPS stimulation, and the forced expression of IL-37b in murine skin DCs promotes tolerogenic DC induction, thereby affecting contact hypersensitivity challenge (140, 141). Among other cytokines, IL-27 was initially considered to be proimmunogenic (142). However, other studies indicated the role of IL-27 in suppressing the differentiation of effector T cells in autoimmune models, such as experimental autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis (MS) (143–145). Still, it remained unknown how IL-27 signaling directly affected DCs and subsequent T cell responses. A more recent report highlighted the role of IL-27 and the immunoregulatory molecule CD39 expressed by DCs. Specifically, CD39, whose expression is induced by IL-27, reduced NLRP3 inflammasome activation in DCs, thereby reducing subsequent Th1 and Th17 effector T cell differentiation (146).

Other extensively studied physiological factors that function in itDC promotion are ligands for the aryl hydrocarbon receptor (AHR), which is important in the regulation of the balance between the formation of regulatory and effector T cells (147). The endogenous ligands of AHR, such as 2-(1′H-indole-3′-carbonyl)-thiazole-4-carboxylic acid methyl ester (ITE), also act directly on DCs by skewing them toward a tolerogenic profile characterized by decreased production of inflammatory cytokines like IL-6 and IL-12 and increased production of suppressive TGF-β and IL-10 (104, 148). In DCs, AHR can induce expression of IDO1, an immunosuppressive enzyme that catabolizes tryptophan into kynurenine (Kyn) and other metabolites (148). Further, the upregulation of IDO1 and Socs2 expression and increased RA production by DCs contribute to a decrease in the proinflammatory cytokine milieu and the subsequent induction of Foxp3+ Treg cells (149). Together, these findings indicate a crucial role of ITE and AHR signaling in the induction of itDCs that could have therapeutic roles in multiple types of autoimmune responses (150).

Vitamin D3 represents another key physiological factor that may induce tolerogenic DCs (151–153). The active form of vitamin D3 induces immunoregulatory properties upon binding to the vitamin D receptor (VDR), which is selectively expressed by various cell types, including intestinal and skin epithelial cells, osteoblasts, CD4+ and CD8+ T cells, and also multiple APCs, including macrophages, monocytes, and DCs (151, 154). VDR agonists increase IL-10 production but decrease expression of IL-12 and CD80/CD86 and CD40 by DCs (155). Additionally, itDCs induced by VDR agonists, such as calcitriol and paricalcitol, are poor inducers of Ag-specific effector T cells but are potent inducers of Treg cells (151–153, 156). It was further demonstrated that DCs may also synthesize the active form of vitamin D3, therefore providing a local source of this crucial immunomodulant, altering immune cell trafficking, and further increasing the DC secretion of the chemokine CCL22, which attracts Treg cells (157–161). Overall, VDR agonists are promising therapeutics for autoimmune diseases, transplantation tolerance, and allergies (151–153, 156).

Other physiological factors may also play a role in itDC promotion. Vasoactive intestinal peptide decreases production of proinflammatory TNF-α and IL-6 and increases production of IL-10 in human DCs despite a pre-exposure to LPS, thereby mediating T cell anergy (162). Also, an addition of seminal plasma to differentiating moDCs yielded high regulatory cytokine and low proinflammatory cytokine production profiles in such moDCs (163).

In addition to these physiological factors, 14-dehydroergosterol (14-DHE), an ergosterol analogue–based compound derived from fermented wheat bran, induces tolerogenic properties in DCs, although the exact mechanisms are unclear (164, 165). Similarly, multiple pharmacological agents, including chemically modified TLR ligands, JAK inhibitors, corticosteroids, cisplatin, antibiotics, probiotics (including bacterial species of the Lactobacillus, Bifidobacterium, and Streptococcus genera), and dietary supplements (such as zinc) have been shown to promote tolerogenic profiles in BMDCs and moDCs. These profiles are characterized by changes at both the transcriptional and translational levels, ultimately leading to decreased production of the inflammatory cytokines TNF-α and IL-6, decreased expression of costimulatory molecules, increased expression of coinhibitory molecules like PD-L1, and the production of the anti-inflammatory cytokines IL-10 and TGF-β (166–169).

Among the intrinsic signaling pathways involved in sensing specific extrinsic factors that induce tolerogenic properties in DCs, Wnt/β-catenin is a major molecular pathway involved in the promotion of itDCs and the increased production of anti-inflammatory cytokines (such as TGF-β, RA, and IL-10) and, conversely, in blocking the production of NF-κB–induced proinflammatory cytokines (32, 33, 67, 170). Deficiencies in Wnt receptors LRP5/6 and β-catenin–signaling mechanisms enhance proinflammatory cytokine production and Th1/Th17 effector responses and increase disease severity in mouse models including colitis and MS (67, 171–174). Noncanonical Wnt signaling mediated by Wnt5a is also involved in the promotion of tolerance by modifying DC maturation and IL-10 production in response to TLR agonists (175). In addition to Wnt/β-catenin, mTOR emerges as an important regulator of DC functions that may also affect tolerogenic mechanisms (176, 177).

Harnessing the tolerogenic functions of DCs for therapeutic applications

The functions of DCs as inducers of tolerance represent important therapeutic opportunities. Modulation of such DC-induced tolerance can help block different forms of autoimmunity and also impact other types of immune responses relevant for transplantations as well as tumor immunology (11). Both ntDCs and itDCs are relevant for such therapeutic manipulations, and the targeted delivery of Ags to DEC-205+ and other DCs has proven to be a powerful way to reinforce tolerance to self-antigens implicated in the autoimmune process (89). For example, the spontaneous induction of peripheral tolerance in response to Ags derived from organs insulated from the immune system (such as the CNS), is likely less efficient (7, 11). This results in an increased potential for autoimmune diseases such as in animal models of MS, which can be readily provoked after an immunization of healthy animals with CNS Ags (7, 178, 179). However, such autoimmune responses can be blocked by tolerance induced by targeted delivery of various tissue-specific Ags to DCs, allowing for efficient Ag presentation to self-reactive T cells (11, 17, 18, 89).

In these initial experiments, DCs were targeted in vivo with anti–DEC-205 chimeric Ab to deliver a potentially encephalitogenic peptide Ag derived from myelin oligodendrocyte glycoprotein, which was genetically fused to the Ab molecule, to prevent subsequently induced EAE (18). These early results were then extended to other EAE models and various encephalitogenic Ags that were delivered through DC-specific molecules, as recently reviewed in Refs. 11 and 89. The targeting of Ags to DCs has also been successful in mediating tolerance in multiple different models of autoimmunity, including diabetes, colitis, and arthritis, as well as in a model of graft-versus-host disease (180–183). Overall, this specific delivery of Ags results in tolerogenic mechanisms that prevent autoimmunity.

In addition to the delivery of Ags specifically targeted to DCs, other studies found that certain formulations of Ags (such as nanoparticles or specifically modified cellular material) could lead to their in vivo acquisition by DCs and to the amelioration of autoimmune processes including EAE and diabetes (184–187). Despite generally lacking cell target specificity, these methods showed promise in the treatment of ongoing autoimmune processes, particularly when additionally coupled with agents known to induce the formation of itDCs under proinflammatory conditions (149). Some of those methods also incorporated DC-specific Abs to enhance the specificity of the delivery system (188), although most of such Ab-coupled immunogenic particles have been tested for new vaccine approaches (189). In addition to controlling autoimmunity, DC-mediated tolerance holds promise in mitigating transplant rejection (as recently reviewed by Thomson et al. in Ref. 190). Importantly, DCs can cooperate with other types of immune cells, such as NKT cells, to prevent graft rejections (191).

In human systems, the most available options thus far have been to induce itDCs ex vivo, analogous to the induction of itDCs from murine BMDCs, and to subsequently treat them with agents that can potentially further promote such itDC differentiation in vivo. Either murine BMDCs or moDCs derived from humans afflicted with an autoimmune disease were treated in vitro with the pharmacologic agents PEGylated–TLR-7 ligand, dexamethasone plus monophosphoryl lipid A, tofacitinib, or prednisolone and were then used to delay disease onset or ameliorate disease severity in diabetes, rheumatoid arthritis, EAE, and myasthenia gravis, respectively (166, 167, 169, 192–194). Also, treatment with IL-10 leads to the formation of itDCs that likely possess clinical relevance (195). Further, the treatment of BMDCs with the antitumor drug cisplatin in conjunction with various TLR agonists results in increased IL-10 production by the BMDCs as well as the prevention of Th1 and Th17 responses (196).

In contrast to the generally beneficial functions of tolerogenic DCs in the prevention of autoimmunities as discussed above, the tumor microenvironment can skew DCs toward tolerogenic functions, thereby diminishing tumor rejection (177, 197–202). In an effort to induce antitumor immunity, multiple DC-based immunotherapies against cancer have been gaining importance, as recently reviewed by Sancho and colleagues (203). Even more breakthroughs that will determine the contributions of various DCs to tumor-immune evasion and allow for the harnessing of such DCs for antitumor therapies are expected.

Conclusions

The recent years have seen a growing understanding of DC functions in both the initiation and the regulation of immune responses. Overall, whereas functions of itDCs contribute to the maintenance of homeostasis under potentially proinflammatory conditions, ntDCs help to establish tolerance under steady-state conditions. Importantly, the new insights are providing us with a framework for exploiting the DC-mediated mechanisms of tolerance for more effective immunotherapies, which will, hopefully, be burdened by fewer side effects.

Disclosures

The authors have no financial conflicts of interest.

Footnotes

  • This work was supported in part by National Institute of Allergy and Infectious Diseases/National Institutes of Health Grant R01AI113903 (to D.H.).

  • Abbreviations used in this article:

    AHR
    aryl hydrocarbon receptor
    BMDC
    bone marrow–derived DC
    BTLA
    B and T lymphocyte associated
    cDC
    conventional DC
    DC
    dendritic cell
    DC-SIGN
    DC-specific ICAM-3–grabbing nonintegrin
    EAE
    experimental autoimmune encephalomyelitis
    HVEM
    herpesvirus entry mediator
    itDC
    induced tolerogenic DC
    LN
    lymph node
    MHCII
    MHC class II
    moDC
    monocyte-derived DC
    MS
    multiple sclerosis
    mTOR
    mammalian target of rapamycin
    ntDC
    natural tolerogenic DC
    PD-1
    programmed death-1
    pDC
    plasmacytoid DC
    PD-L1
    programmed death ligand-1
    PRR
    pattern recognition receptor
    pTreg
    peripherally formed Treg
    RA
    retinoic acid
    Treg
    regulatory T
    tTreg
    thymically derived regulatory T
    VDR
    vitamin D receptor.

  • Received September 16, 2019.
  • Accepted October 4, 2019.

References

  1. ↵
    1. Klein, L.,
    2. E. A. Robey,
    3. C. S. Hsieh
    . 2019. Central CD4+ T cell tolerance: deletion versus regulatory T cell differentiation. Nat. Rev. Immunol. 19: 7–18.
    OpenUrl
  2. ↵
    1. Enouz, S.,
    2. L. Carrié,
    3. D. Merkler,
    4. M. J. Bevan,
    5. D. Zehn
    . 2012. Autoreactive T cells bypass negative selection and respond to self-antigen stimulation during infection. J. Exp. Med. 209: 1769–1779.
    OpenUrlAbstract/FREE Full Text
  3. ↵
    1. Nelson, R. W.,
    2. D. Beisang,
    3. N. J. Tubo,
    4. T. Dileepan,
    5. D. L. Wiesner,
    6. K. Nielsen,
    7. M. Wüthrich,
    8. B. S. Klein,
    9. D. I. Kotov,
    10. J. A. Spanier, et al
    . 2015. T cell receptor cross-reactivity between similar foreign and self peptides influences naive cell population size and autoimmunity. [Published erratum appears in 2015 Immunity 42: 1212–1213.] Immunity 42: 95–107.
    OpenUrlCrossRefPubMed
  4. ↵
    1. Zehn, D.,
    2. M. J. Bevan
    . 2006. T cells with low avidity for a tissue-restricted antigen routinely evade central and peripheral tolerance and cause autoimmunity. Immunity 25: 261–270.
    OpenUrlCrossRefPubMed
    1. Anderson, A. C.,
    2. L. B. Nicholson,
    3. K. L. Legge,
    4. V. Turchin,
    5. H. Zaghouani,
    6. V. K. Kuchroo
    . 2000. High frequency of autoreactive myelin proteolipid protein-specific T cells in the periphery of naive mice: mechanisms of selection of the self-reactive repertoire. J. Exp. Med. 191: 761–770.
    OpenUrlAbstract/FREE Full Text
    1. Bouneaud, C.,
    2. P. Kourilsky,
    3. P. Bousso
    . 2000. Impact of negative selection on the T cell repertoire reactive to a self-peptide: a large fraction of T cell clones escapes clonal deletion. Immunity 13: 829–840.
    OpenUrlCrossRefPubMed
  7. ↵
    1. Jones, A.,
    2. D. Hawiger
    . 2017. Peripherally induced regulatory T cells: recruited protectors of the central nervous system against autoimmune neuroinflammation. Front. Immunol. 8: 532.
    OpenUrl
  8. ↵
    1. Josefowicz, S. Z.,
    2. L. F. Lu,
    3. A. Y. Rudensky
    . 2012. Regulatory T cells: mechanisms of differentiation and function. Annu. Rev. Immunol. 30: 531–564.
    OpenUrlCrossRefPubMed
  9. ↵
    1. Ooi, J. D.,
    2. J. Petersen,
    3. Y. H. Tan,
    4. M. Huynh,
    5. Z. J. Willett,
    6. S. H. Ramarathinam,
    7. P. J. Eggenhuizen,
    8. K. L. Loh,
    9. K. A. Watson,
    10. P. Y. Gan, et al
    . 2017. Dominant protection from HLA-linked autoimmunity by antigen-specific regulatory T cells. Nature 545: 243–247.
    OpenUrlCrossRefPubMed
  10. ↵
    1. Koehli, S.,
    2. D. Naeher,
    3. V. Galati-Fournier,
    4. D. Zehn,
    5. E. Palmer
    . 2014. Optimal T-cell receptor affinity for inducing autoimmunity. Proc. Natl. Acad. Sci. USA 111: 17248–17253.
    OpenUrlAbstract/FREE Full Text
  11. ↵
    1. Iberg, C. A.,
    2. A. Jones,
    3. D. Hawiger
    . 2017. Dendritic cells as inducers of peripheral tolerance. Trends Immunol. 38: 793–804.
    OpenUrl
  12. ↵
    1. Esterházy, D.,
    2. J. Loschko,
    3. M. London,
    4. V. Jove,
    5. T. Y. Oliveira,
    6. D. Mucida
    . 2016. Classical dendritic cells are required for dietary antigen-mediated induction of peripheral T(reg) cells and tolerance. Nat. Immunol. 17: 545–555.
    OpenUrlCrossRefPubMed
  13. ↵
    1. Ohta, T.,
    2. M. Sugiyama,
    3. H. Hemmi,
    4. C. Yamazaki,
    5. S. Okura,
    6. I. Sasaki,
    7. Y. Fukuda,
    8. T. Orimo,
    9. K. J. Ishii,
    10. K. Hoshino, et al
    . 2016. Crucial roles of XCR1-expressing dendritic cells and the XCR1-XCL1 chemokine axis in intestinal immune homeostasis. Sci. Rep. 6: 23505.
    OpenUrlCrossRefPubMed
    1. Wang, L.,
    2. Z. Li,
    3. B. Ciric,
    4. F. Safavi,
    5. G. X. Zhang,
    6. A. Rostami
    . 2016. Selective depletion of CD11c+ CD11b+ dendritic cells partially abrogates tolerogenic effects of intravenous MOG in murine EAE. Eur. J. Immunol. 46: 2454–2466.
    OpenUrl
    1. Ohnmacht, C.,
    2. A. Pullner,
    3. S. B. King,
    4. I. Drexler,
    5. S. Meier,
    6. T. Brocker,
    7. D. Voehringer
    . 2009. Constitutive ablation of dendritic cells breaks self-tolerance of CD4 T cells and results in spontaneous fatal autoimmunity. J. Exp. Med. 206: 549–559.
    OpenUrlAbstract/FREE Full Text
  16. ↵
    1. Fukaya, T.,
    2. R. Murakami,
    3. H. Takagi,
    4. K. Sato,
    5. Y. Sato,
    6. H. Otsuka,
    7. M. Ohno,
    8. A. Hijikata,
    9. O. Ohara,
    10. M. Hikida, et al
    . 2012. Conditional ablation of CD205+ conventional dendritic cells impacts the regulation of T-cell immunity and homeostasis in vivo. Proc. Natl. Acad. Sci. USA 109: 11288–11293.
    OpenUrlAbstract/FREE Full Text
  17. ↵
    1. Hawiger, D.,
    2. K. Inaba,
    3. Y. Dorsett,
    4. M. Guo,
    5. K. Mahnke,
    6. M. Rivera,
    7. J. V. Ravetch,
    8. R. M. Steinman,
    9. M. C. Nussenzweig
    . 2001. Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. J. Exp. Med. 194: 769–779.
    OpenUrlAbstract/FREE Full Text
  18. ↵
    1. Hawiger, D.,
    2. R. F. Masilamani,
    3. E. Bettelli,
    4. V. K. Kuchroo,
    5. M. C. Nussenzweig
    . 2004. Immunological unresponsiveness characterized by increased expression of CD5 on peripheral T cells induced by dendritic cells in vivo. Immunity 20: 695–705.
    OpenUrlCrossRefPubMed
    1. Probst, H. C.,
    2. K. McCoy,
    3. T. Okazaki,
    4. T. Honjo,
    5. M. van den Broek
    . 2005. Resting dendritic cells induce peripheral CD8+ T cell tolerance through PD-1 and CTLA-4. Nat. Immunol. 6: 280–286.
    OpenUrlCrossRefPubMed
  20. ↵
    1. Belz, G. T.,
    2. G. M. Behrens,
    3. C. M. Smith,
    4. J. F. Miller,
    5. C. Jones,
    6. K. Lejon,
    7. C. G. Fathman,
    8. S. N. Mueller,
    9. K. Shortman,
    10. F. R. Carbone,
    11. W. R. Heath
    . 2002. The CD8alpha(+) dendritic cell is responsible for inducing peripheral self-tolerance to tissue-associated antigens. J. Exp. Med. 196: 1099–1104.
    OpenUrlAbstract/FREE Full Text
  21. ↵
    1. Murphy, T. L.,
    2. G. E. Grajales-Reyes,
    3. X. Wu,
    4. R. Tussiwand,
    5. C. G. Briseño,
    6. A. Iwata,
    7. N. M. Kretzer,
    8. V. Durai,
    9. K. M. Murphy
    . 2016. Transcriptional control of dendritic cell development. Annu. Rev. Immunol. 34: 93–119.
    OpenUrlCrossRefPubMed
  22. ↵
    1. Merad, M.,
    2. P. Sathe,
    3. J. Helft,
    4. J. Miller,
    5. A. Mortha
    . 2013. The dendritic cell lineage: ontogeny and function of dendritic cells and their subsets in the steady state and the inflamed setting. Annu. Rev. Immunol. 31: 563–604.
    OpenUrlCrossRefPubMed
  23. ↵
    1. Durai, V.,
    2. K. M. Murphy
    . 2016. Functions of murine dendritic cells. Immunity 45: 719–736.
    OpenUrlCrossRefPubMed
  24. ↵
    1. Guilliams, M.,
    2. C. A. Dutertre,
    3. C. L. Scott,
    4. N. McGovern,
    5. D. Sichien,
    6. S. Chakarov,
    7. S. Van Gassen,
    8. J. Chen,
    9. M. Poidinger,
    10. S. De Prijck, et al
    . 2016. Unsupervised high-dimensional analysis aligns dendritic cells across tissues and species. Immunity 45: 669–684.
    OpenUrlCrossRefPubMed
  25. ↵
    1. Swiecki, M.,
    2. M. Colonna
    . 2015. The multifaceted biology of plasmacytoid dendritic cells. Nat. Rev. Immunol. 15: 471–485.
    OpenUrlCrossRefPubMed
  26. ↵
    1. Ziegler-Heitbrock, L.,
    2. P. Ancuta,
    3. S. Crowe,
    4. M. Dalod,
    5. V. Grau,
    6. D. N. Hart,
    7. P. J. Leenen,
    8. Y. J. Liu,
    9. G. MacPherson,
    10. G. J. Randolph, et al
    . 2010. Nomenclature of monocytes and dendritic cells in blood. Blood 116: e74–e80.
    OpenUrlAbstract/FREE Full Text
  27. ↵
    1. Steinman, R. M.
    2012. Decisions about dendritic cells: past, present, and future. Annu. Rev. Immunol. 30: 1–22.
    OpenUrlCrossRefPubMed
  28. ↵
    1. Mellman, I.
    2013. Dendritic cells: master regulators of the immune response. Cancer Immunol. Res. 1: 145–149.
    OpenUrlAbstract/FREE Full Text
  29. ↵
    1. Iwasaki, A.,
    2. R. Medzhitov
    . 2015. Control of adaptive immunity by the innate immune system. Nat. Immunol. 16: 343–353.
    OpenUrlCrossRefPubMed
  30. ↵
    1. Dalod, M.,
    2. R. Chelbi,
    3. B. Malissen,
    4. T. Lawrence
    . 2014. Dendritic cell maturation: functional specialization through signaling specificity and transcriptional programming. EMBO J. 33: 1104–1116.
    OpenUrlAbstract/FREE Full Text
  31. ↵
    1. Lutz, M. B.,
    2. G. Schuler
    . 2002. Immature, semi-mature and fully mature dendritic cells: which signals induce tolerance or immunity? Trends Immunol. 23: 445–449.
    OpenUrlCrossRefPubMed
  32. ↵
    1. Manicassamy, S.,
    2. B. Pulendran
    . 2011. Dendritic cell control of tolerogenic responses. Immunol. Rev. 241: 206–227.
    OpenUrlCrossRefPubMed
  33. ↵
    1. Pulendran, B.
    2015. The varieties of immunological experience: of pathogens, stress, and dendritic cells. Annu. Rev. Immunol. 33: 563–606.
    OpenUrlCrossRefPubMed
  34. ↵
    1. Maldonado, R. A.,
    2. U. H. von Andrian
    . 2010. How tolerogenic dendritic cells induce regulatory T cells. Adv. Immunol. 108: 111–165.
    OpenUrlCrossRefPubMed
  35. ↵
    1. Steinman, R. M.,
    2. D. Hawiger,
    3. K. Liu,
    4. L. Bonifaz,
    5. D. Bonnyay,
    6. K. Mahnke,
    7. T. Iyoda,
    8. J. Ravetch,
    9. M. Dhodapkar,
    10. K. Inaba,
    11. M. Nussenzweig
    . 2003. Dendritic cell function in vivo during the steady state: a role in peripheral tolerance. Ann. N. Y. Acad. Sci. 987: 15–25.
    OpenUrlCrossRefPubMed
  36. ↵
    1. Zhang, M.,
    2. H. Tang,
    3. Z. Guo,
    4. H. An,
    5. X. Zhu,
    6. W. Song,
    7. J. Guo,
    8. X. Huang,
    9. T. Chen,
    10. J. Wang,
    11. X. Cao
    . 2004. Splenic stroma drives mature dendritic cells to differentiate into regulatory dendritic cells. [Published erratum appears in 2014 Nat. Immunol. 15: 1090.] Nat. Immunol. 5: 1124–1133.
    OpenUrlCrossRefPubMed
  37. ↵
    1. Vander Lugt, B.,
    2. J. Riddell,
    3. A. A. Khan,
    4. J. A. Hackney,
    5. J. Lesch,
    6. J. DeVoss,
    7. M. T. Weirauch,
    8. H. Singh,
    9. I. Mellman
    . 2017. Transcriptional determinants of tolerogenic and immunogenic states during dendritic cell maturation. J. Cell Biol. 216: 779–792.
    OpenUrlAbstract/FREE Full Text
  38. ↵
    1. Ardouin, L.,
    2. H. Luche,
    3. R. Chelbi,
    4. S. Carpentier,
    5. A. Shawket,
    6. F. Montanana Sanchis,
    7. C. Santa Maria,
    8. P. Grenot,
    9. Y. Alexandre,
    10. C. Grégoire, et al
    . 2016. Broad and largely concordant molecular changes characterize tolerogenic and immunogenic dendritic cell maturation in thymus and periphery. Immunity 45: 305–318.
    OpenUrl
  39. ↵
    1. Jiang, A.,
    2. O. Bloom,
    3. S. Ono,
    4. W. Cui,
    5. J. Unternaehrer,
    6. S. Jiang,
    7. J. A. Whitney,
    8. J. Connolly,
    9. J. Banchereau,
    10. I. Mellman
    . 2007. Disruption of E-cadherin-mediated adhesion induces a functionally distinct pathway of dendritic cell maturation. Immunity 27: 610–624.
    OpenUrlCrossRefPubMed
  40. ↵
    1. Baratin, M.,
    2. C. Foray,
    3. O. Demaria,
    4. M. Habbeddine,
    5. E. Pollet,
    6. J. Maurizio,
    7. C. Verthuy,
    8. S. Davanture,
    9. H. Azukizawa,
    10. A. Flores-Langarica, et al
    . 2015. Homeostatic NF-κB signaling in steady-state migratory dendritic cells regulates immune homeostasis and tolerance. Immunity 42: 627–639.
    OpenUrlCrossRefPubMed
  41. ↵
    1. Jones, A.,
    2. A. Opejin,
    3. J. G. Henderson,
    4. C. Gross,
    5. R. Jain,
    6. J. A. Epstein,
    7. R. A. Flavell,
    8. D. Hawiger
    . 2015. Peripherally induced tolerance depends on peripheral regulatory T cells that require Hopx to inhibit intrinsic IL-2 expression. J. Immunol. 195: 1489–1497.
    OpenUrlAbstract/FREE Full Text
  42. ↵
    1. Jones, A.,
    2. J. Bourque,
    3. L. Kuehm,
    4. A. Opejin,
    5. R. M. Teague,
    6. C. Gross,
    7. D. Hawiger
    . 2016. Immunomodulatory functions of BTLA and HVEM govern induction of extrathymic regulatory T cells and tolerance by dendritic cells. Immunity 45: 1066–1077.
    OpenUrlCrossRef
  43. ↵
    1. Kretschmer, K.,
    2. I. Apostolou,
    3. D. Hawiger,
    4. K. Khazaie,
    5. M. C. Nussenzweig,
    6. H. von Boehmer
    . 2005. Inducing and expanding regulatory T cell populations by foreign antigen. Nat. Immunol. 6: 1219–1227.
    OpenUrlCrossRefPubMed
  44. ↵
    1. Kalekar, L. A.,
    2. D. L. Mueller
    . 2017. Relationship between CD4 regulatory T cells and anergy in vivo. J. Immunol. 198: 2527–2533.
    OpenUrlAbstract/FREE Full Text
  45. ↵
    1. Eisenbarth, S. C.
    2019. Dendritic cell subsets in T cell programming: location dictates function. Nat. Rev. Immunol. 19: 89–103.
    OpenUrl
    1. Baptista, A. P.,
    2. A. Gola,
    3. Y. Huang,
    4. P. Milanez-Almeida,
    5. P. Torabi-Parizi,
    6. J. F. Urban Jr..,
    7. V. S. Shapiro,
    8. M. Y. Gerner,
    9. R. N. Germain
    . 2019. The chemoattractant receptor Ebi2 drives intranodal naive CD4+ T cell peripheralization to promote effective adaptive immunity. Immunity 50: 1188–1201.e6.
    OpenUrl
  47. ↵
    1. Esterházy, D.,
    2. M. C. C. Canesso,
    3. L. Mesin,
    4. P. A. Muller,
    5. T. B. R. de Castro,
    6. A. Lockhart,
    7. M. ElJalby,
    8. A. M. C. Faria,
    9. D. Mucida
    . 2019. Compartmentalized gut lymph node drainage dictates adaptive immune responses. Nature 569: 126–130.
    OpenUrl
  48. ↵
    1. Dudziak, D.,
    2. A. O. Kamphorst,
    3. G. F. Heidkamp,
    4. V. R. Buchholz,
    5. C. Trumpfheller,
    6. S. Yamazaki,
    7. C. Cheong,
    8. K. Liu,
    9. H. W. Lee,
    10. C. G. Park, et al
    . 2007. Differential antigen processing by dendritic cell subsets in vivo. Science 315: 107–111.
    OpenUrlAbstract/FREE Full Text
  49. ↵
    1. Bourque, J.,
    2. D. Hawiger
    . 2018. Immunomodulatory bonds of the partnership between dendritic cells and T cells. Crit. Rev. Immunol. 38: 379–401.
    OpenUrl
  50. ↵
    1. Sharpe, A. H.,
    2. K. E. Pauken
    . 2018. The diverse functions of the PD1 inhibitory pathway. Nat. Rev. Immunol. 18: 153–167.
    OpenUrlCrossRefPubMed
  51. ↵
    1. Walunas, T. L.,
    2. C. Y. Bakker,
    3. J. A. Bluestone
    . 1996. CTLA-4 ligation blocks CD28-dependent T cell activation. [Published erratum appears in 1996 J. Exp. Med. 184: 301.] J. Exp. Med. 183: 2541–2550.
    OpenUrlAbstract/FREE Full Text
    1. Qureshi, O. S.,
    2. Y. Zheng,
    3. K. Nakamura,
    4. K. Attridge,
    5. C. Manzotti,
    6. E. M. Schmidt,
    7. J. Baker,
    8. L. E. Jeffery,
    9. S. Kaur,
    10. Z. Briggs, et al
    . 2011. Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4. Science 332: 600–603.
    OpenUrlAbstract/FREE Full Text
  53. ↵
    1. Bucktrout, S. L.,
    2. J. A. Bluestone,
    3. F. Ramsdell
    . 2018. Recent advances in immunotherapies: from infection and autoimmunity, to cancer, and back again. Genome Med. 10: 79.
    OpenUrl
  54. ↵
    1. Akbari, O.,
    2. G. J. Freeman,
    3. E. H. Meyer,
    4. E. A. Greenfield,
    5. T. T. Chang,
    6. A. H. Sharpe,
    7. G. Berry,
    8. R. H. DeKruyff,
    9. D. T. Umetsu
    . 2002. Antigen-specific regulatory T cells develop via the ICOS-ICOS-ligand pathway and inhibit allergen-induced airway hyperreactivity. Nat. Med. 8: 1024–1032.
    OpenUrlCrossRefPubMed
    1. Ito, T.,
    2. M. Yang,
    3. Y.-H. Wang,
    4. R. Lande,
    5. J. Gregorio,
    6. O. A. Perng,
    7. X.-F. Qin,
    8. Y.-J. Liu,
    9. M. Gilliet
    . 2007. Plasmacytoid dendritic cells prime IL-10-producing T regulatory cells by inducible costimulator ligand. J. Exp. Med. 204: 105–115.
    OpenUrlAbstract/FREE Full Text
    1. Dong, C.,
    2. A. E. Juedes,
    3. U. A. Temann,
    4. S. Shresta,
    5. J. P. Allison,
    6. N. H. Ruddle,
    7. R. A. Flavell
    . 2001. ICOS co-stimulatory receptor is essential for T-cell activation and function. Nature 409: 97–101.
    OpenUrlCrossRefPubMed
    1. Iwai, H.,
    2. M. Abe,
    3. S. Hirose,
    4. F. Tsushima,
    5. K. Tezuka,
    6. H. Akiba,
    7. H. Yagita,
    8. K. Okumura,
    9. H. Kohsaka,
    10. N. Miyasaka,
    11. M. Azuma
    . 2003. Involvement of inducible costimulator-B7 homologous protein costimulatory pathway in murine lupus nephritis. J. Immunol. 171: 2848–2854.
    OpenUrlAbstract/FREE Full Text
  58. ↵
    1. Hawiger, D.,
    2. E. Tran,
    3. W. Du,
    4. C. J. Booth,
    5. L. Wen,
    6. C. Dong,
    7. R. A. Flavell
    . 2008. ICOS mediates the development of insulin-dependent diabetes mellitus in nonobese diabetic mice. J. Immunol. 180: 3140–3147.
    OpenUrlAbstract/FREE Full Text
  59. ↵
    1. Zhang, X.,
    2. H. Huang,
    3. J. Yuan,
    4. D. Sun,
    5. W. S. Hou,
    6. J. Gordon,
    7. J. Xiang
    . 2005. CD4-8- dendritic cells prime CD4+ T regulatory 1 cells to suppress antitumor immunity. J. Immunol. 175: 2931–2937.
    OpenUrlAbstract/FREE Full Text
  60. ↵
    1. Li, M. O.,
    2. R. A. Flavell
    . 2008. Contextual regulation of inflammation: a duet by transforming growth factor-beta and interleukin-10. Immunity 28: 468–476.
    OpenUrlCrossRefPubMed
  61. ↵
    1. Chen, W.,
    2. W. Jin,
    3. N. Hardegen,
    4. K. J. Lei,
    5. L. Li,
    6. N. Marinos,
    7. G. McGrady,
    8. S. M. Wahl
    . 2003. Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J. Exp. Med. 198: 1875–1886.
    OpenUrlAbstract/FREE Full Text
    1. Fantini, M. C.,
    2. C. Becker,
    3. G. Monteleone,
    4. F. Pallone,
    5. P. R. Galle,
    6. M. F. Neurath
    . 2004. Cutting edge: TGF-beta induces a regulatory phenotype in CD4+CD25- T cells through Foxp3 induction and down-regulation of Smad7. J. Immunol. 172: 5149–5153.
    OpenUrlAbstract/FREE Full Text
    1. Liu, Y.,
    2. P. Zhang,
    3. J. Li,
    4. A. B. Kulkarni,
    5. S. Perruche,
    6. W. Chen
    . 2008. A critical function for TGF-beta signaling in the development of natural CD4+CD25+Foxp3+ regulatory T cells. Nat. Immunol. 9: 632–640.
    OpenUrlCrossRefPubMed
    1. Mangan, P. R.,
    2. L. E. Harrington,
    3. D. B. O’Quinn,
    4. W. S. Helms,
    5. D. C. Bullard,
    6. C. O. Elson,
    7. R. D. Hatton,
    8. S. M. Wahl,
    9. T. R. Schoeb,
    10. C. T. Weaver
    . 2006. Transforming growth factor-beta induces development of the T(H)17 lineage. Nature 441: 231–234.
    OpenUrlCrossRefPubMed
  65. ↵
    1. Bettelli, E.,
    2. Y. Carrier,
    3. W. Gao,
    4. T. Korn,
    5. T. B. Strom,
    6. M. Oukka,
    7. H. L. Weiner,
    8. V. K. Kuchroo
    . 2006. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 441: 235–238.
    OpenUrlCrossRefPubMed
  66. ↵
    1. Mucida, D.,
    2. Y. Park,
    3. G. Kim,
    4. O. Turovskaya,
    5. I. Scott,
    6. M. Kronenberg,
    7. H. Cheroutre
    . 2007. Reciprocal TH17 and regulatory T cell differentiation mediated by retinoic acid. Science 317: 256–260.
    OpenUrlAbstract/FREE Full Text
  67. ↵
    1. Manicassamy, S.,
    2. B. Reizis,
    3. R. Ravindran,
    4. H. Nakaya,
    5. R. M. Salazar-Gonzalez,
    6. Y. C. Wang,
    7. B. Pulendran
    . 2010. Activation of beta-catenin in dendritic cells regulates immunity versus tolerance in the intestine. Science 329: 849–853.
    OpenUrlAbstract/FREE Full Text
    1. Nozaki, Y.,
    2. T. Yamagata,
    3. M. Sugiyama,
    4. S. Ikoma,
    5. K. Kinoshita,
    6. M. Funauchi
    . 2006. Anti-inflammatory effect of all-trans-retinoic acid in inflammatory arthritis. Clin. Immunol. 119: 272–279.
    OpenUrlCrossRefPubMed
    1. Xiao, S.,
    2. H. Jin,
    3. T. Korn,
    4. S. M. Liu,
    5. M. Oukka,
    6. B. Lim,
    7. V. K. Kuchroo
    . 2008. Retinoic acid increases Foxp3+ regulatory T cells and inhibits development of Th17 cells by enhancing TGF-beta-driven Smad3 signaling and inhibiting IL-6 and IL-23 receptor expression. J. Immunol. 181: 2277–2284.
    OpenUrlAbstract/FREE Full Text
  70. ↵
    1. Massacesi, L.,
    2. E. Castigli,
    3. M. Vergelli,
    4. J. Olivotto,
    5. A. L. Abbamondi,
    6. F. Sarlo,
    7. L. Amaducci
    . 1991. Immunosuppressive activity of 13-cis-retinoic acid and prevention of experimental autoimmune encephalomyelitis in rats. J. Clin. Invest. 88: 1331–1337.
    OpenUrlCrossRefPubMed
  71. ↵
    1. Henderson, J. G.,
    2. A. Opejin,
    3. A. Jones,
    4. C. Gross,
    5. D. Hawiger
    . 2015. CD5 instructs extrathymic regulatory T cell development in response to self and tolerizing antigens. Immunity 42: 471–483.
    OpenUrlCrossRefPubMed
  72. ↵
    1. Bourque, J.,
    2. D. Hawiger
    . 2019. The BTLA-HVEM-CD5 immunoregulatory axis-an instructive mechanism governing pTreg cell differentiation. Front. Immunol. 10: 1163.
    OpenUrl
  73. ↵
    1. Steinman, R. M.,
    2. D. Hawiger,
    3. M. C. Nussenzweig
    . 2003. Tolerogenic dendritic cells. Annu. Rev. Immunol. 21: 685–711.
    OpenUrlCrossRefPubMed
  74. ↵
    1. Albert, M. L.,
    2. S. F. Pearce,
    3. L. M. Francisco,
    4. B. Sauter,
    5. P. Roy,
    6. R. L. Silverstein,
    7. N. Bhardwaj
    . 1998. Immature dendritic cells phagocytose apoptotic cells via alphavbeta5 and CD36, and cross-present antigens to cytotoxic T lymphocytes. J. Exp. Med. 188: 1359–1368.
    OpenUrlAbstract/FREE Full Text
  75. ↵
    1. Kurts, C.,
    2. J. F. Miller,
    3. R. M. Subramaniam,
    4. F. R. Carbone,
    5. W. R. Heath
    . 1998. Major histocompatibility complex class I-restricted cross-presentation is biased towards high dose antigens and those released during cellular destruction. J. Exp. Med. 188: 409–414.
    OpenUrlAbstract/FREE Full Text
  76. ↵
    1. Steinberg, M. W.,
    2. Y. Huang,
    3. Y. Wang-Zhu,
    4. C. F. Ware,
    5. H. Cheroutre,
    6. M. Kronenberg
    . 2013. BTLA interaction with HVEM expressed on CD8(+) T cells promotes survival and memory generation in response to a bacterial infection. PLoS One 8: e77992.
    1. Shui, J. W.,
    2. M. W. Steinberg,
    3. M. Kronenberg
    . 2011. Regulation of inflammation, autoimmunity, and infection immunity by HVEM-BTLA signaling. J. Leukoc. Biol. 89: 517–523.
    OpenUrlCrossRefPubMed
    1. Murphy, T. L.,
    2. K. M. Murphy
    . 2010. Slow down and survive: enigmatic immunoregulation by BTLA and HVEM. Annu. Rev. Immunol. 28: 389–411.
    OpenUrlCrossRefPubMed
  79. ↵
    1. So, T.,
    2. M. Croft
    . 2013. Regulation of PI-3-kinase and Akt signaling in T lymphocytes and other cells by TNFR family molecules. Front. Immunol. 4: 139.
    OpenUrlPubMed
  80. ↵
    1. Iyoda, T.,
    2. S. Shimoyama,
    3. K. Liu,
    4. Y. Omatsu,
    5. Y. Akiyama,
    6. Y. Maeda,
    7. K. Takahara,
    8. R. M. Steinman,
    9. K. Inaba
    . 2002. The CD8+ dendritic cell subset selectively endocytoses dying cells in culture and in vivo. J. Exp. Med. 195: 1289–1302.
    OpenUrlAbstract/FREE Full Text
  81. ↵
    1. Luckashenak, N.,
    2. S. Schroeder,
    3. K. Endt,
    4. D. Schmidt,
    5. K. Mahnke,
    6. M. F. Bachmann,
    7. P. Marconi,
    8. C. A. Deeg,
    9. T. Brocker
    . 2008. Constitutive crosspresentation of tissue antigens by dendritic cells controls CD8+ T cell tolerance in vivo. Immunity 28: 521–532.
    OpenUrlCrossRefPubMed
  82. ↵
    1. Rigotti, A.,
    2. S. L. Acton,
    3. M. Krieger
    . 1995. The class B scavenger receptors SR-BI and CD36 are receptors for anionic phospholipids. J. Biol. Chem. 270: 16221–16224.
    OpenUrlAbstract/FREE Full Text
  83. ↵
    1. Immunological Genome Project Consortium
    . 2008. The Immunological Genome Project: networks of gene expression in immune cells. Nat. Immunol. 9: 1091–1094.
    OpenUrlCrossRefPubMed
  84. ↵
    1. Perry, J. S. A.,
    2. E. V. Russler-Germain,
    3. Y. W. Zhou,
    4. W. Purtha,
    5. M. L. Cooper,
    6. J. Choi,
    7. M. A. Schroeder,
    8. V. Salazar,
    9. T. Egawa,
    10. B. C. Lee, et al
    . 2018. Transfer of cell-surface antigens by scavenger receptor CD36 promotes thymic regulatory T cell receptor repertoire development and allo-tolerance. [Published erratum appears in 2018 Immunity 48: 1271.] Immunity 48: 923–936.e4.
    OpenUrl
  85. ↵
    1. Kushwah, R.,
    2. J. Wu,
    3. J. R. Oliver,
    4. G. Jiang,
    5. J. Zhang,
    6. K. A. Siminovitch,
    7. J. Hu
    . 2010. Uptake of apoptotic DC converts immature DC into tolerogenic DC that induce differentiation of Foxp3+ Treg. Eur. J. Immunol. 40: 1022–1035.
    OpenUrlCrossRefPubMed
  86. ↵
    1. Urban, B. C.,
    2. N. Willcox,
    3. D. J. Roberts
    . 2001. A role for CD36 in the regulation of dendritic cell function. Proc. Natl. Acad. Sci. USA 98: 8750–8755.
    OpenUrlAbstract/FREE Full Text
  87. ↵
    1. Sachet, M.,
    2. Y. Y. Liang,
    3. R. Oehler
    . 2017. The immune response to secondary necrotic cells. Apoptosis 22: 1189–1204.
    OpenUrlCrossRef
  88. ↵
    1. Sancho, D.,
    2. O. P. Joffre,
    3. A. M. Keller,
    4. N. C. Rogers,
    5. D. Martínez,
    6. P. Hernanz-Falcón,
    7. I. Rosewell,
    8. C. Reis e Sousa
    . 2009. Identification of a dendritic cell receptor that couples sensing of necrosis to immunity. Nature 458: 899–903.
    OpenUrlCrossRefPubMed
  89. ↵
    1. Iberg, C. A.,
    2. D. Hawiger
    . 2019. Advancing immunomodulation by in vivo antigen delivery to DEC-205 and other cell surface molecules using recombinant chimeric antibodies. Int. Immunopharmacol. 73: 575–580.
    OpenUrl
  90. ↵
    1. Azukizawa, H.,
    2. A. Döhler,
    3. N. Kanazawa,
    4. A. Nayak,
    5. M. Lipp,
    6. B. Malissen,
    7. I. Autenrieth,
    8. I. Katayama,
    9. M. Riemann,
    10. F. Weih, et al
    . 2011. Steady state migratory RelB+ langerin+ dermal dendritic cells mediate peripheral induction of antigen-specific CD4+ CD25+ Foxp3+ regulatory T cells. Eur. J. Immunol. 41: 1420–1434.
    OpenUrlCrossRefPubMed
    1. Guilliams, M.,
    2. K. Crozat,
    3. S. Henri,
    4. S. Tamoutounour,
    5. P. Grenot,
    6. E. Devilard,
    7. B. de Bovis,
    8. L. Alexopoulou,
    9. M. Dalod,
    10. B. Malissen
    . 2010. Skin-draining lymph nodes contain dermis-derived CD103(-) dendritic cells that constitutively produce retinoic acid and induce Foxp3(+) regulatory T cells. Blood 115: 1958–1968.
    OpenUrlAbstract/FREE Full Text
  92. ↵
    1. Idoyaga, J.,
    2. C. Fiorese,
    3. L. Zbytnuik,
    4. A. Lubkin,
    5. J. Miller,
    6. B. Malissen,
    7. D. Mucida,
    8. M. Merad,
    9. R. M. Steinman
    . 2013. Specialized role of migratory dendritic cells in peripheral tolerance induction. J. Clin. Invest. 123: 844–854.
    OpenUrlCrossRefPubMed
  93. ↵
    1. Volz, T.,
    2. Y. Skabytska,
    3. E. Guenova,
    4. K. M. Chen,
    5. J. S. Frick,
    6. C. J. Kirschning,
    7. S. Kaesler,
    8. M. Röcken,
    9. T. Biedermann
    . 2014. Nonpathogenic bacteria alleviating atopic dermatitis inflammation induce IL-10-producing dendritic cells and regulatory Tr1 cells. J. Invest. Dermatol. 134: 96–104.
    OpenUrlCrossRefPubMed
    1. Krempski, J.,
    2. L. Karyampudi,
    3. M. D. Behrens,
    4. C. L. Erskine,
    5. L. Hartmann,
    6. H. Dong,
    7. E. L. Goode,
    8. K. R. Kalli,
    9. K. L. Knutson
    . 2011. Tumor-infiltrating programmed death receptor-1+ dendritic cells mediate immune suppression in ovarian cancer. J. Immunol. 186: 6905–6913.
    OpenUrlAbstract/FREE Full Text
  95. ↵
    1. Weiner, H. L.
    2001. The mucosal milieu creates tolerogenic dendritic cells and T(R)1 and T(H)3 regulatory cells. Nat. Immunol. 2: 671–672.
    OpenUrlCrossRefPubMed
    1. Owen, J. L.,
    2. M. Mohamadzadeh
    . 2013. Microbial activation of gut dendritic cells and the control of mucosal immunity. J. Interferon Cytokine Res. 33: 619–631.
    OpenUrl
    1. Lambrecht, B. N.,
    2. J. B. Prins,
    3. H. C. Hoogsteden
    . 2001. Lung dendritic cells and host immunity to infection. Eur. Respir. J. 18: 692–704.
    OpenUrlAbstract/FREE Full Text
    1. Naik, S.,
    2. N. Bouladoux,
    3. C. Wilhelm,
    4. M. J. Molloy,
    5. R. Salcedo,
    6. W. Kastenmuller,
    7. C. Deming,
    8. M. Quinones,
    9. L. Koo,
    10. S. Conlan, et al
    . 2012. Compartmentalized control of skin immunity by resident commensals. Science 337: 1115–1119.
    OpenUrlAbstract/FREE Full Text
  99. ↵
    1. Menges, M.,
    2. S. Rössner,
    3. C. Voigtländer,
    4. H. Schindler,
    5. N. A. Kukutsch,
    6. C. Bogdan,
    7. K. Erb,
    8. G. Schuler,
    9. M. B. Lutz
    . 2002. Repetitive injections of dendritic cells matured with tumor necrosis factor alpha induce antigen-specific protection of mice from autoimmunity. J. Exp. Med. 195: 15–21.
    OpenUrlAbstract/FREE Full Text
  100. ↵
    1. Naik, S.,
    2. N. Bouladoux,
    3. J. L. Linehan,
    4. S. J. Han,
    5. O. J. Harrison,
    6. C. Wilhelm,
    7. S. Conlan,
    8. S. Himmelfarb,
    9. A. L. Byrd,
    10. C. Deming, et al
    . 2015. Commensal-dendritic-cell interaction specifies a unique protective skin immune signature. Nature 520: 104–108.
    OpenUrlCrossRefPubMed
  101. ↵
    1. Akbari, O.,
    2. R. H. DeKruyff,
    3. D. T. Umetsu
    . 2001. Pulmonary dendritic cells producing IL-10 mediate tolerance induced by respiratory exposure to antigen. Nat. Immunol. 2: 725–731.
    OpenUrlCrossRefPubMed
  102. ↵
    1. Tsoumakidou, M.,
    2. S. Tousa,
    3. M. Semitekolou,
    4. P. Panagiotou,
    5. A. Panagiotou,
    6. I. Morianos,
    7. E. Litsiou,
    8. A. I. Trochoutsou,
    9. M. Konstantinou,
    10. K. Potaris, et al
    . 2014. Tolerogenic signaling by pulmonary CD1c+ dendritic cells induces regulatory T cells in patients with chronic obstructive pulmonary disease by IL-27/IL-10/inducible costimulator ligand. J. Allergy Clin. Immunol. 134: 944–954.e8.
    OpenUrl
  103. ↵
    1. Wawrzyniak, M.,
    2. L. O’Mahony,
    3. M. Akdis
    . 2017. Role of regulatory cells in oral tolerance. Allergy Asthma Immunol. Res. 9: 107–115.
    OpenUrl
  104. ↵
    1. Quintana, F. J.,
    2. G. Murugaiyan,
    3. M. F. Farez,
    4. M. Mitsdoerffer,
    5. A. M. Tukpah,
    6. E. J. Burns,
    7. H. L. Weiner
    . 2010. An endogenous aryl hydrocarbon receptor ligand acts on dendritic cells and T cells to suppress experimental autoimmune encephalomyelitis. Proc. Natl. Acad. Sci. USA 107: 20768–20773.
    OpenUrlAbstract/FREE Full Text
    1. Takenaka, M. C.,
    2. L. P. Araujo,
    3. J. T. Maricato,
    4. V. M. Nascimento,
    5. M. G. Guereschi,
    6. R. M. Rezende,
    7. F. J. Quintana,
    8. A. S. Basso
    . 2016. Norepinephrine controls effector T cell differentiation through β2-adrenergic receptor-mediated inhibition of NF-κB and AP-1 in dendritic cells. J. Immunol. 196: 637–644.
    OpenUrlAbstract/FREE Full Text
    1. Atarashi, K.,
    2. T. Tanoue,
    3. T. Shima,
    4. A. Imaoka,
    5. T. Kuwahara,
    6. Y. Momose,
    7. G. Cheng,
    8. S. Yamasaki,
    9. T. Saito,
    10. Y. Ohba, et al
    . 2011. Induction of colonic regulatory T cells by indigenous Clostridium species. Science 331: 337–341.
    OpenUrlAbstract/FREE Full Text
  107. ↵
    1. Li, J.,
    2. F. Ahmet,
    3. L. C. Sullivan,
    4. A. G. Brooks,
    5. S. J. Kent,
    6. R. De Rose,
    7. A. M. Salazar,
    8. C. Reis e Sousa,
    9. K. Shortman,
    10. M. H. Lahoud, et al
    . 2015. Antibodies targeting Clec9A promote strong humoral immunity without adjuvant in mice and non-human primates. Eur. J. Immunol. 45: 854–864.
    OpenUrlCrossRefPubMed
  108. ↵
    1. Coombes, J. L.,
    2. K. R. Siddiqui,
    3. C. V. Arancibia-Cárcamo,
    4. J. Hall,
    5. C. M. Sun,
    6. Y. Belkaid,
    7. F. Powrie
    . 2007. A functionally specialized population of mucosal CD103+ DCs induces Foxp3+ regulatory T cells via a TGF-beta and retinoic acid-dependent mechanism. J. Exp. Med. 204: 1757–1764.
    OpenUrlAbstract/FREE Full Text
  109. ↵
    1. Sun, C. M.,
    2. J. A. Hall,
    3. R. B. Blank,
    4. N. Bouladoux,
    5. M. Oukka,
    6. J. R. Mora,
    7. Y. Belkaid
    . 2007. Small intestine lamina propria dendritic cells promote de novo generation of Foxp3 T reg cells via retinoic acid. J. Exp. Med. 204: 1775–1785.
    OpenUrlAbstract/FREE Full Text
  110. ↵
    1. Josefowicz, S. Z.,
    2. R. E. Niec,
    3. H. Y. Kim,
    4. P. Treuting,
    5. T. Chinen,
    6. Y. Zheng,
    7. D. T. Umetsu,
    8. A. Y. Rudensky
    . 2012. Extrathymically generated regulatory T cells control mucosal TH2 inflammation. Nature 482: 395–399.
    OpenUrlCrossRefPubMed
  111. ↵
    1. Nutsch, K.,
    2. J. N. Chai,
    3. T. L. Ai,
    4. E. Russler-Germain,
    5. T. Feehley,
    6. C. R. Nagler,
    7. C. S. Hsieh
    . 2016. Rapid and efficient generation of regulatory T cells to commensal antigens in the periphery. Cell Rep 17: 206–220.
    OpenUrlCrossRefPubMed
  112. ↵
    1. Price, J. D.,
    2. C. Hotta-Iwamura,
    3. Y. Zhao,
    4. N. M. Beauchamp,
    5. K. V. Tarbell
    . 2015. DCIR2+ cDC2 DCs and Zbtb32 restore CD4+ T-cell tolerance and inhibit diabetes. Diabetes 64: 3521–3531.
    OpenUrlAbstract/FREE Full Text
  113. ↵
    1. Weiner, H. L.,
    2. A. P. da Cunha,
    3. F. Quintana,
    4. H. Wu
    . 2011. Oral tolerance. Immunol. Rev. 241: 241–259.
    OpenUrlCrossRefPubMed
  114. ↵
    1. Medzhitov, R.,
    2. C. A. Janeway Jr.
    . 2002. Decoding the patterns of self and nonself by the innate immune system. Science 296: 298–300.
    OpenUrlAbstract/FREE Full Text
    1. Hacini-Rachinel, F.,
    2. M. Gomez de Agüero,
    3. R. Kanjarawi,
    4. L. Moro-Sibilot,
    5. J. B. Le Luduec,
    6. C. Macari,
    7. G. Boschetti,
    8. E. Bardel,
    9. P. Langella,
    10. B. Dubois,
    11. D. Kaiserlian
    . 2018. Intestinal dendritic cell licensing through toll-like receptor 4 is required for oral tolerance in allergic contact dermatitis. J. Allergy Clin. Immunol. 141: 163–170.
    OpenUrl
  116. ↵
    1. Manicassamy, S.,
    2. R. Ravindran,
    3. J. Deng,
    4. H. Oluoch,
    5. T. L. Denning,
    6. S. P. Kasturi,
    7. K. M. Rosenthal,
    8. B. D. Evavold,
    9. B. Pulendran
    . 2009. Toll-like receptor 2-dependent induction of vitamin A-metabolizing enzymes in dendritic cells promotes T regulatory responses and inhibits autoimmunity. Nat. Med. 15: 401–409.
    OpenUrlCrossRefPubMed
  117. ↵
    1. Caparrós, E.,
    2. P. Munoz,
    3. E. Sierra-Filardi,
    4. D. Serrano-Gómez,
    5. A. Puig-Kröger,
    6. J. L. Rodríguez-Fernández,
    7. M. Mellado,
    8. J. Sancho,
    9. M. Zubiaur,
    10. A. L. Corbí
    . 2006. DC-SIGN ligation on dendritic cells results in ERK and PI3K activation and modulates cytokine production. Blood 107: 3950–3958.
    OpenUrlAbstract/FREE Full Text
  118. ↵
    1. Qian, C.,
    2. H. An,
    3. Y. Yu,
    4. S. Liu,
    5. X. Cao
    . 2007. TLR agonists induce regulatory dendritic cells to recruit Th1 cells via preferential IP-10 secretion and inhibit Th1 proliferation. Blood 109: 3308–3315.
    OpenUrlAbstract/FREE Full Text
  119. ↵
    1. Abdollahi-Roodsaz, S.,
    2. L. A. Joosten,
    3. M. I. Koenders,
    4. I. Devesa,
    5. M. F. Roelofs,
    6. T. R. Radstake,
    7. M. Heuvelmans-Jacobs,
    8. S. Akira,
    9. M. J. Nicklin,
    10. F. Ribeiro-Dias,
    11. W. B. van den Berg
    . 2008. Stimulation of TLR2 and TLR4 differentially skews the balance of T cells in a mouse model of arthritis. J. Clin. Invest. 118: 205–216.
    OpenUrlCrossRefPubMed
  120. ↵
    1. Depaolo, R. W.,
    2. F. Tang,
    3. I. Kim,
    4. M. Han,
    5. N. Levin,
    6. N. Ciletti,
    7. A. Lin,
    8. D. Anderson,
    9. O. Schneewind,
    10. B. Jabri
    . 2008. Toll-like receptor 6 drives differentiation of tolerogenic dendritic cells and contributes to LcrV-mediated plague pathogenesis. Cell Host Microbe 4: 350–361.
    OpenUrlCrossRefPubMed
  121. ↵
    1. Dillon, S.,
    2. S. Agrawal,
    3. K. Banerjee,
    4. J. Letterio,
    5. T. L. Denning,
    6. K. Oswald-Richter,
    7. D. J. Kasprowicz,
    8. K. Kellar,
    9. J. Pare,
    10. T. van Dyke, et al
    . 2006. Yeast zymosan, a stimulus for TLR2 and dectin-1, induces regulatory antigen-presenting cells and immunological tolerance. J. Clin. Invest. 116: 916–928.
    OpenUrlCrossRefPubMed
  122. ↵
    1. Gringhuis, S. I.,
    2. J. den Dunnen,
    3. M. Litjens,
    4. B. van Het Hof,
    5. Y. van Kooyk,
    6. T. B. Geijtenbeek
    . 2007. C-type lectin DC-SIGN modulates toll-like receptor signaling via Raf-1 kinase-dependent acetylation of transcription factor NF-kappaB. Immunity 26: 605–616.
    OpenUrlCrossRefPubMed
  123. ↵
    1. Cruz-Aguilar, M.,
    2. A. I. Castillo-Rodal,
    3. A. Schcolnik-Cabrera,
    4. L. C. Bonifaz,
    5. G. Molina,
    6. Y. López-Vidal
    . 2016. TLR4 and DC-SIGN receptors recognized Mycobacterium scrofulaceum promoting semi-activated phenotype on bone marrow dendritic cells. Tuberculosis (Edinb.) 99: 31–40.
    OpenUrl
  124. ↵
    1. Singh, N.,
    2. A. Gurav,
    3. S. Sivaprakasam,
    4. E. Brady,
    5. R. Padia,
    6. H. Shi,
    7. M. Thangaraju,
    8. P. D. Prasad,
    9. S. Manicassamy,
    10. D. H. Munn, et al
    . 2014. Activation of Gpr109a, receptor for niacin and the commensal metabolite butyrate, suppresses colonic inflammation and carcinogenesis. Immunity 40: 128–139.
    OpenUrlCrossRefPubMed
  125. ↵
    1. Liu, C.,
    2. J. Wu,
    3. J. Zhu,
    4. C. Kuei,
    5. J. Yu,
    6. J. Shelton,
    7. S. W. Sutton,
    8. X. Li,
    9. S. J. Yun,
    10. T. Mirzadegan, et al
    . 2009. Lactate inhibits lipolysis in fat cells through activation of an orphan G-protein-coupled receptor, GPR81. J. Biol. Chem. 284: 2811–2822.
    OpenUrlAbstract/FREE Full Text
  126. ↵
    1. Ranganathan, P.,
    2. A. Shanmugam,
    3. D. Swafford,
    4. A. Suryawanshi,
    5. P. Bhattacharjee,
    6. M. S. Hussein,
    7. P. A. Koni,
    8. P. D. Prasad,
    9. Z. B. Kurago,
    10. M. Thangaraju, et al
    . 2018. GPR81, a cell-surface receptor for lactate, regulates intestinal homeostasis and protects mice from experimental colitis. J. Immunol. 200: 1781–1789.
    OpenUrlAbstract/FREE Full Text
  127. ↵
    1. Engering, A.,
    2. T. B. Geijtenbeek,
    3. S. J. van Vliet,
    4. M. Wijers,
    5. E. van Liempt,
    6. N. Demaurex,
    7. A. Lanzavecchia,
    8. J. Fransen,
    9. C. G. Figdor,
    10. V. Piguet,
    11. Y. van Kooyk
    . 2002. The dendritic cell-specific adhesion receptor DC-SIGN internalizes antigen for presentation to T cells. J. Immunol. 168: 2118–2126.
    OpenUrlAbstract/FREE Full Text
  128. ↵
    1. Conde, P.,
    2. M. Rodriguez,
    3. W. van der Touw,
    4. A. Jimenez,
    5. M. Burns,
    6. J. Miller,
    7. M. Brahmachary,
    8. H. M. Chen,
    9. P. Boros,
    10. F. Rausell-Palamos, et al
    . 2015. DC-SIGN(+) macrophages control the induction of transplantation tolerance. Immunity 42: 1143–1158.
    OpenUrl
  129. ↵
    1. Geijtenbeek, T. B.,
    2. J. den Dunnen,
    3. S. I. Gringhuis
    . 2009. Pathogen recognition by DC-SIGN shapes adaptive immunity. Future Microbiol. 4: 879–890.
    OpenUrlCrossRefPubMed
    1. Gringhuis, S. I.,
    2. J. den Dunnen,
    3. M. Litjens,
    4. M. van der Vlist,
    5. T. B. Geijtenbeek
    . 2009. Carbohydrate-specific signaling through the DC-SIGN signalosome tailors immunity to Mycobacterium tuberculosis, HIV-1 and Helicobacter pylori. Nat. Immunol. 10: 1081–1088.
    OpenUrlCrossRefPubMed
  131. ↵
    1. Steeghs, L.,
    2. S. J. van Vliet,
    3. H. Uronen-Hansson,
    4. A. van Mourik,
    5. A. Engering,
    6. M. Sanchez-Hernandez,
    7. N. Klein,
    8. R. Callard,
    9. J. P. van Putten,
    10. P. van der Ley, et al
    . 2006. Neisseria meningitidis expressing lgtB lipopolysaccharide targets DC-SIGN and modulates dendritic cell function. Cell. Microbiol. 8: 316–325.
    OpenUrlCrossRefPubMed
  132. ↵
    1. Steinbrink, K.,
    2. M. Wölfl,
    3. H. Jonuleit,
    4. J. Knop,
    5. A. H. Enk
    . 1997. Induction of tolerance by IL-10-treated dendritic cells. J. Immunol. 159: 4772–4780.
    OpenUrlAbstract
  133. ↵
    1. Torres-Aguilar, H.,
    2. S. R. Aguilar-Ruiz,
    3. G. González-Pérez,
    4. R. Munguía,
    5. S. Bajaña,
    6. M. A. Meraz-Ríos,
    7. C. Sánchez-Torres
    . 2010. Tolerogenic dendritic cells generated with different immunosuppressive cytokines induce antigen-specific anergy and regulatory properties in memory CD4+ T cells. J. Immunol. 184: 1765–1775.
    OpenUrlAbstract/FREE Full Text
  134. ↵
    1. Mucida, D.,
    2. H. Cheroutre
    . 2007. TGFbeta and retinoic acid intersect in immune-regulation. Cell Adhes. Migr. 1: 142–144.
    OpenUrl
  135. ↵
    1. Iliev, I. D.,
    2. I. Spadoni,
    3. E. Mileti,
    4. G. Matteoli,
    5. A. Sonzogni,
    6. G. M. Sampietro,
    7. D. Foschi,
    8. F. Caprioli,
    9. G. Viale,
    10. M. Rescigno
    . 2009. Human intestinal epithelial cells promote the differentiation of tolerogenic dendritic cells. Gut 58: 1481–1489.
    OpenUrlAbstract/FREE Full Text
    1. Iwata, M.,
    2. A. Hirakiyama,
    3. Y. Eshima,
    4. H. Kagechika,
    5. C. Kato,
    6. S. Y. Song
    . 2004. Retinoic acid imprints gut-homing specificity on T cells. Immunity 21: 527–538.
    OpenUrlCrossRefPubMed
  137. ↵
    1. Bakdash, G.,
    2. L. T. Vogelpoel,
    3. T. M. van Capel,
    4. M. L. Kapsenberg,
    5. E. C. de Jong
    . 2015. Retinoic acid primes human dendritic cells to induce gut-homing, IL-10-producing regulatory T cells. Mucosal Immunol. 8: 265–278.
    OpenUrlCrossRefPubMed
  138. ↵
    1. Chamorro, S.,
    2. J. J. García-Vallejo,
    3. W. W. Unger,
    4. R. J. Fernandes,
    5. S. C. Bruijns,
    6. S. Laban,
    7. B. O. Roep,
    8. B. A. ’t Hart,
    9. Y. van Kooyk
    . 2009. TLR triggering on tolerogenic dendritic cells results in TLR2 up-regulation and a reduced proinflammatory immune program. J. Immunol. 183: 2984–2994.
    OpenUrlAbstract/FREE Full Text
  139. ↵
    1. Collison, L. W.,
    2. C. J. Workman,
    3. T. T. Kuo,
    4. K. Boyd,
    5. Y. Wang,
    6. K. M. Vignali,
    7. R. Cross,
    8. D. Sehy,
    9. R. S. Blumberg,
    10. D. A. Vignali
    . 2007. The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature 450: 566–569.
    OpenUrlCrossRefPubMed
  140. ↵
    1. Nold, M. F.,
    2. C. A. Nold-Petry,
    3. J. A. Zepp,
    4. B. E. Palmer,
    5. P. Bufler,
    6. C. A. Dinarello
    . 2010. IL-37 is a fundamental inhibitor of innate immunity. Nat. Immunol. 11: 1014–1022.
    OpenUrlCrossRefPubMed
  141. ↵
    1. Luo, Y.,
    2. X. Cai,
    3. S. Liu,
    4. S. Wang,
    5. C. A. Nold-Petry,
    6. M. F. Nold,
    7. P. Bufler,
    8. D. Norris,
    9. C. A. Dinarello,
    10. M. Fujita
    . 2014. Suppression of antigen-specific adaptive immunity by IL-37 via induction of tolerogenic dendritic cells. Proc. Natl. Acad. Sci. USA 111: 15178–15183.
    OpenUrlAbstract/FREE Full Text
  142. ↵
    1. Hunter, C. A.,
    2. R. Kastelein
    . 2012. Interleukin-27: balancing protective and pathological immunity. Immunity 37: 960–969.
    OpenUrlCrossRefPubMed
  143. ↵
    1. Batten, M.,
    2. J. Li,
    3. S. Yi,
    4. N. M. Kljavin,
    5. D. M. Danilenko,
    6. S. Lucas,
    7. J. Lee,
    8. F. J. de Sauvage,
    9. N. Ghilardi
    . 2006. Interleukin 27 limits autoimmune encephalomyelitis by suppressing the development of interleukin 17-producing T cells. Nat. Immunol. 7: 929–936.
    OpenUrlCrossRefPubMed
    1. Fitzgerald, D. C.,
    2. B. Ciric,
    3. T. Touil,
    4. H. Harle,
    5. J. Grammatikopolou,
    6. J. Das Sarma,
    7. B. Gran,
    8. G. X. Zhang,
    9. A. Rostami
    . 2007. Suppressive effect of IL-27 on encephalitogenic Th17 cells and the effector phase of experimental autoimmune encephalomyelitis. J. Immunol. 179: 3268–3275.
    OpenUrlAbstract/FREE Full Text
  145. ↵
    1. Kastelein, R. A.,
    2. C. A. Hunter,
    3. D. J. Cua
    . 2007. Discovery and biology of IL-23 and IL-27: related but functionally distinct regulators of inflammation. Annu. Rev. Immunol. 25: 221–242.
    OpenUrlCrossRefPubMed
  146. ↵
    1. Mascanfroni, I. D.,
    2. A. Yeste,
    3. S. M. Vieira,
    4. E. J. Burns,
    5. B. Patel,
    6. I. Sloma,
    7. Y. Wu,
    8. L. Mayo,
    9. R. Ben-Hamo,
    10. S. Efroni, et al
    . 2013. IL-27 acts on DCs to suppress the T cell response and autoimmunity by inducing expression of the immunoregulatory molecule CD39. Nat. Immunol. 14: 1054–1063.
    OpenUrlCrossRefPubMed
  147. ↵
    1. Quintana, F. J.,
    2. A. S. Basso,
    3. A. H. Iglesias,
    4. T. Korn,
    5. M. F. Farez,
    6. E. Bettelli,
    7. M. Caccamo,
    8. M. Oukka,
    9. H. L. Weiner
    . 2008. Control of T(reg) and T(H)17 cell differentiation by the aryl hydrocarbon receptor. Nature 453: 65–71.
    OpenUrlCrossRefPubMed
  148. ↵
    1. Nguyen, N. T.,
    2. A. Kimura,
    3. T. Nakahama,
    4. I. Chinen,
    5. K. Masuda,
    6. K. Nohara,
    7. Y. Fujii-Kuriyama,
    8. T. Kishimoto
    . 2010. Aryl hydrocarbon receptor negatively regulates dendritic cell immunogenicity via a kynurenine-dependent mechanism. Proc. Natl. Acad. Sci. USA 107: 19961–19966.
    OpenUrlAbstract/FREE Full Text
  149. ↵
    1. Yeste, A.,
    2. M. C. Takenaka,
    3. I. D. Mascanfroni,
    4. M. Nadeau,
    5. J. E. Kenison,
    6. B. Patel,
    7. A. M. Tukpah,
    8. J. A. Babon,
    9. M. DeNicola,
    10. S. C. Kent, et al
    . 2016. Tolerogenic nanoparticles inhibit T cell-mediated autoimmunity through SOCS2. Sci. Signal. 9: ra61.
    OpenUrlAbstract/FREE Full Text
  150. ↵
    1. Takenaka, M. C.,
    2. F. J. Quintana
    . 2017. Tolerogenic dendritic cells. Semin. Immunopathol. 39: 113–120.
    OpenUrl
  151. ↵
    1. Adorini, L.,
    2. G. Penna
    . 2009. Dendritic cell tolerogenicity: a key mechanism in immunomodulation by vitamin D receptor agonists. Hum. Immunol. 70: 345–352.
    OpenUrlCrossRefPubMed
    1. Barragan, M.,
    2. M. Good,
    3. J. K. Kolls
    . 2015. Regulation of dendritic cell function by vitamin D. Nutrients 7: 8127–8151.
    OpenUrl
  153. ↵
    1. Bscheider, M.,
    2. E. C. Butcher
    . 2016. Vitamin D immunoregulation through dendritic cells. Immunology 148: 227–236.
    OpenUrl
  154. ↵
    1. Wang, Y.,
    2. J. Zhu,
    3. H. F. DeLuca
    . 2012. Where is the vitamin D receptor? Arch. Biochem. Biophys. 523: 123–133.
    OpenUrlCrossRefPubMed
  155. ↵
    1. Penna, G.,
    2. S. Amuchastegui,
    3. N. Giarratana,
    4. K. C. Daniel,
    5. M. Vulcano,
    6. S. Sozzani,
    7. L. Adorini
    . 2007. 1,25-Dihydroxyvitamin D3 selectively modulates tolerogenic properties in myeloid but not plasmacytoid dendritic cells. J. Immunol. 178: 145–153.
    OpenUrlAbstract/FREE Full Text
  156. ↵
    1. Sochorová, K.,
    2. V. Budinský,
    3. D. Rozková,
    4. Z. Tobiasová,
    5. S. Dusilová-Sulková,
    6. R. Spísek,
    7. J. Bartůnková
    . 2009. Paricalcitol (19-nor-1,25-dihydroxyvitamin D2) and calcitriol (1,25-dihydroxyvitamin D3) exert potent immunomodulatory effects on dendritic cells and inhibit induction of antigen-specific T cells. Clin. Immunol. 133: 69–77.
    OpenUrlCrossRefPubMed
  157. ↵
    1. Sigmundsdottir, H.,
    2. J. Pan,
    3. G. F. Debes,
    4. C. Alt,
    5. A. Habtezion,
    6. D. Soler,
    7. E. C. Butcher
    . 2007. DCs metabolize sunlight-induced vitamin D3 to ‘program’ T cell attraction to the epidermal chemokine CCL27. Nat. Immunol. 8: 285–293.
    OpenUrlCrossRefPubMed
    1. Hewison, M.,
    2. L. Freeman,
    3. S. V. Hughes,
    4. K. N. Evans,
    5. R. Bland,
    6. A. G. Eliopoulos,
    7. M. D. Kilby,
    8. P. A. Moss,
    9. R. Chakraverty
    . 2003. Differential regulation of vitamin D receptor and its ligand in human monocyte-derived dendritic cells. J. Immunol. 170: 5382–5390.
    OpenUrlAbstract/FREE Full Text
    1. Enioutina, E. Y.,
    2. D. Bareyan,
    3. R. A. Daynes
    . 2009. TLR-induced local metabolism of vitamin D3 plays an important role in the diversification of adaptive immune responses. J. Immunol. 182: 4296–4305.
    OpenUrlAbstract/FREE Full Text
    1. Széles, L.,
    2. G. Keresztes,
    3. D. Töröcsik,
    4. Z. Balajthy,
    5. L. Krenács,
    6. S. Póliska,
    7. A. Steinmeyer,
    8. U. Zuegel,
    9. M. Pruenster,
    10. A. Rot,
    11. L. Nagy
    . 2009. 1,25-dihydroxyvitamin D3 is an autonomous regulator of the transcriptional changes leading to a tolerogenic dendritic cell phenotype. J. Immunol. 182: 2074–2083.
    OpenUrlAbstract/FREE Full Text
  161. ↵
    1. Chu, C. C.,
    2. N. Ali,
    3. P. Karagiannis,
    4. P. Di Meglio,
    5. A. Skowera,
    6. L. Napolitano,
    7. G. Barinaga,
    8. K. Grys,
    9. E. Sharif-Paghaleh,
    10. S. N. Karagiannis, et al
    . 2012. Resident CD141 (BDCA3)+ dendritic cells in human skin produce IL-10 and induce regulatory T cells that suppress skin inflammation. J. Exp. Med. 209: 935–945.
    OpenUrlAbstract/FREE Full Text
  162. ↵
    1. Gonzalez-Rey, E.,
    2. A. Chorny,
    3. A. Fernandez-Martin,
    4. D. Ganea,
    5. M. Delgado
    . 2006. Vasoactive intestinal peptide generates human tolerogenic dendritic cells that induce CD4 and CD8 regulatory T cells. Blood 107: 3632–3638.
    OpenUrlAbstract/FREE Full Text
  163. ↵
    1. Remes Lenicov, F.,
    2. C. Rodriguez Rodrigues,
    3. J. Sabatté,
    4. M. Cabrini,
    5. C. Jancic,
    6. M. Ostrowski,
    7. A. Merlotti,
    8. H. Gonzalez,
    9. A. Alonso,
    10. R. A. Pasqualini, et al
    . 2012. Semen promotes the differentiation of tolerogenic dendritic cells. J. Immunol. 189: 4777–4786.
    OpenUrlAbstract/FREE Full Text
  164. ↵
    1. Ano, Y.,
    2. K. Ikado,
    3. K. Shindo,
    4. H. Koizumi,
    5. D. Fujiwara
    . 2017. Identification of 14-dehydroergosterol as a novel anti-inflammatory compound inducing tolerogenic dendritic cells. Sci. Rep. 7: 13903.
    OpenUrl
  165. ↵
    1. Sugihara, Y.,
    2. S. Ikushima,
    3. M. Miyake,
    4. T. Kirisako,
    5. Y. Yada,
    6. D. Fujiwara
    . 2018. Improvement of skin conditions by ingestion of Aspergillus kawachii (Koji) extract containing 14-dehydroergosterol in a randomized, double-blind, controlled trial. Clin. Cosmet. Investig. Dermatol. 11: 115–124.
    OpenUrl
  166. ↵
    1. Hayashi, T.,
    2. S. Yao,
    3. B. Crain,
    4. V. J. Promessi,
    5. L. Shyu,
    6. C. Sheng,
    7. M. Kang,
    8. H. B. Cottam,
    9. D. A. Carson,
    10. M. Corr
    . 2015. Induction of tolerogenic dendritic cells by a PEGylated TLR7 ligand for treatment of type 1 diabetes. PLoS One 10: e0129867.
  167. ↵
    1. Zhou, Y.,
    2. X. Leng,
    3. S. Luo,
    4. Z. Su,
    5. X. Luo,
    6. H. Guo,
    7. C. Mo,
    8. Q. Zou,
    9. Y. Liu,
    10. Y. Wang
    . 2016. Tolerogenic dendritic cells generated with tofacitinib ameliorate experimental autoimmune encephalomyelitis through modulation of Th17/Treg balance. J. Immunol. Res. 2016: 5021537.
    1. Kwon, H. K.,
    2. C. G. Lee,
    3. J. S. So,
    4. C. S. Chae,
    5. J. S. Hwang,
    6. A. Sahoo,
    7. J. H. Nam,
    8. J. H. Rhee,
    9. K. C. Hwang,
    10. S. H. Im
    . 2010. Generation of regulatory dendritic cells and CD4+Foxp3+ T cells by probiotics administration suppresses immune disorders. Proc. Natl. Acad. Sci. USA 107: 2159–2164.
    OpenUrlAbstract/FREE Full Text
  169. ↵
    1. García-González, P.,
    2. R. Morales,
    3. L. Hoyos,
    4. J. Maggi,
    5. J. Campos,
    6. B. Pesce,
    7. D. Gárate,
    8. M. Larrondo,
    9. R. González,
    10. L. Soto, et al
    . 2013. A short protocol using dexamethasone and monophosphoryl lipid A generates tolerogenic dendritic cells that display a potent migratory capacity to lymphoid chemokines. J. Transl. Med. 11: 128.
    OpenUrl
  170. ↵
    1. Shan, M.,
    2. M. Gentile,
    3. J. R. Yeiser,
    4. A. C. Walland,
    5. V. U. Bornstein,
    6. K. Chen,
    7. B. He,
    8. L. Cassis,
    9. A. Bigas,
    10. M. Cols, et al
    . 2013. Mucus enhances gut homeostasis and oral tolerance by delivering immunoregulatory signals. Science 342: 447–453.
    OpenUrlAbstract/FREE Full Text
  171. ↵
    1. Suryawanshi, A.,
    2. I. Manoharan,
    3. Y. Hong,
    4. D. Swafford,
    5. T. Majumdar,
    6. M. M. Taketo,
    7. B. Manicassamy,
    8. P. A. Koni,
    9. M. Thangaraju,
    10. Z. Sun, et al
    . 2015. Canonical wnt signaling in dendritic cells regulates Th1/Th17 responses and suppresses autoimmune neuroinflammation. J. Immunol. 194: 3295–3304.
    OpenUrlAbstract/FREE Full Text
    1. Reuter, S.,
    2. H. Martin,
    3. H. Beckert,
    4. M. Bros,
    5. E. Montermann,
    6. C. Belz,
    7. A. Heinz,
    8. S. Ohngemach,
    9. U. Sahin,
    10. M. Stassen, et al
    . 2014. The Wnt/β-catenin pathway attenuates experimental allergic airway disease. J. Immunol. 193: 485–495.
    OpenUrlAbstract/FREE Full Text
    1. Swafford, D.,
    2. S. Manicassamy
    . 2015. Wnt signaling in dendritic cells: its role in regulation of immunity and tolerance. Discov. Med. 19: 303–310.
    OpenUrl
  174. ↵
    1. Swafford, D.,
    2. A. Shanmugam,
    3. P. Ranganathan,
    4. M. S. Hussein,
    5. P. A. Koni,
    6. P. D. Prasad,
    7. M. Thangaraju,
    8. S. Manicassamy
    . 2018. Canonical Wnt signaling in CD11c+ APCs regulates microbiota-induced inflammation and immune cell homeostasis in the colon. J. Immunol. 200: 3259–3268.
    OpenUrlAbstract/FREE Full Text
  175. ↵
    1. Valencia, J.,
    2. C. Hernández-López,
    3. V. G. Martínez,
    4. L. Hidalgo,
    5. A. G. Zapata,
    6. Á. Vicente,
    7. A. Varas,
    8. R. Sacedón
    . 2011. Wnt5a skews dendritic cell differentiation to an unconventional phenotype with tolerogenic features. J. Immunol. 187: 4129–4139.
    OpenUrlAbstract/FREE Full Text
  176. ↵
    1. Hackstein, H.,
    2. T. Taner,
    3. A. F. Zahorchak,
    4. A. E. Morelli,
    5. A. J. Logar,
    6. A. Gessner,
    7. A. W. Thomson
    . 2003. Rapamycin inhibits IL-4--induced dendritic cell maturation in vitro and dendritic cell mobilization and function in vivo. Blood 101: 4457–4463.
    OpenUrlAbstract/FREE Full Text
  177. ↵
    1. Wang, Y.,
    2. X. Du,
    3. J. Wei,
    4. L. Long,
    5. H. Tan,
    6. C. Guy,
    7. Y. Dhungana,
    8. C. Qian,
    9. G. Neale,
    10. Y. X. Fu, et al
    . 2019. LKB1 orchestrates dendritic cell metabolic quiescence and anti-tumor immunity. Cell Res. 29: 391–405.
    OpenUrl
  178. ↵
    1. Kuchroo, V. K.,
    2. A. C. Anderson,
    3. H. Waldner,
    4. M. Munder,
    5. E. Bettelli,
    6. L. B. Nicholson
    . 2002. T cell response in experimental autoimmune encephalomyelitis (EAE): role of self and cross-reactive antigens in shaping, tuning, and regulating the autopathogenic T cell repertoire. Annu. Rev. Immunol. 20: 101–123.
    OpenUrlCrossRefPubMed
  179. ↵
    1. Simmons, S. B.,
    2. E. R. Pierson,
    3. S. Y. Lee,
    4. J. M. Goverman
    . 2013. Modeling the heterogeneity of multiple sclerosis in animals. Trends Immunol. 34: 410–422.
    OpenUrlCrossRefPubMed
  180. ↵
    1. Mukherjee, G.,
    2. A. Geliebter,
    3. J. Babad,
    4. P. Santamaria,
    5. D. V. Serreze,
    6. G. J. Freeman,
    7. K. V. Tarbell,
    8. A. Sharpe,
    9. T. P. DiLorenzo
    . 2013. DEC-205-mediated antigen targeting to steady-state dendritic cells induces deletion of diabetogenic CD8+ T cells independently of PD-1 and PD-L1. Int. Immunol. 25: 651–660.
    OpenUrlCrossRefPubMed
    1. Wadwa, M.,
    2. R. Klopfleisch,
    3. J. Buer,
    4. A. M. Westendorf
    . 2016. Targeting antigens to Dec-205 on dendritic cells induces immune protection in experimental colitis in mice. Eur. J. Microbiol. Immunol. (Bp.) 6: 1–8.
    OpenUrl
    1. Spiering, R.,
    2. B. Margry,
    3. C. Keijzer,
    4. C. Petzold,
    5. A. Hoek,
    6. J. Wagenaar-Hilbers,
    7. R. van der Zee,
    8. W. van Eden,
    9. K. Kretschmer,
    10. F. Broere
    . 2015. DEC205+ dendritic cell-targeted tolerogenic vaccination promotes immune tolerance in experimental autoimmune arthritis. J. Immunol. 194: 4804–4813.
    OpenUrlAbstract/FREE Full Text
  183. ↵
    1. Ettinger, M.,
    2. I. K. Gratz,
    3. C. Gruber,
    4. C. Hauser-Kronberger,
    5. T. S. Johnson,
    6. K. Mahnke,
    7. J. Thalhamer,
    8. H. Hintner,
    9. D. Peckl-Schmid,
    10. J. W. Bauer
    . 2012. Targeting of the hNC16A collagen domain to dendritic cells induces tolerance to human type XVII collagen. Exp. Dermatol. 21: 395–398.
    OpenUrlPubMed
  184. ↵
    1. Maldonado, R. A.,
    2. R. A. LaMothe,
    3. J. D. Ferrari,
    4. A. H. Zhang,
    5. R. J. Rossi,
    6. P. N. Kolte,
    7. A. P. Griset,
    8. C. O’Neil,
    9. D. H. Altreuter,
    10. E. Browning, et al
    . 2015. Polymeric synthetic nanoparticles for the induction of antigen-specific immunological tolerance. Proc. Natl. Acad. Sci. USA 112: E156–E165.
    OpenUrlAbstract/FREE Full Text
    1. Clemente-Casares, X.,
    2. J. Blanco,
    3. P. Ambalavanan,
    4. J. Yamanouchi,
    5. S. Singha,
    6. C. Fandos,
    7. S. Tsai,
    8. J. Wang,
    9. N. Garabatos,
    10. C. Izquierdo, et al
    . 2016. Expanding antigen-specific regulatory networks to treat autoimmunity. Nature 530: 434–440.
    OpenUrlCrossRefPubMed
    1. Getts, D. R.,
    2. A. J. Martin,
    3. D. P. McCarthy,
    4. R. L. Terry,
    5. Z. N. Hunter,
    6. W. T. Yap,
    7. M. T. Getts,
    8. M. Pleiss,
    9. X. Luo,
    10. N. J. King, et al
    . 2012. Microparticles bearing encephalitogenic peptides induce T-cell tolerance and ameliorate experimental autoimmune encephalomyelitis. Nat. Biotechnol. 30: 1217–1224.
    OpenUrlCrossRefPubMed
  187. ↵
    1. Miller, S. D.,
    2. D. M. Turley,
    3. J. R. Podojil
    . 2007. Antigen-specific tolerance strategies for the prevention and treatment of autoimmune disease. Nat. Rev. Immunol. 7: 665–677.
    OpenUrlCrossRefPubMed
  188. ↵
    1. Stead, S. O.,
    2. S. J. P. McInnes,
    3. S. Kireta,
    4. P. D. Rose,
    5. S. Jesudason,
    6. D. Rojas-Canales,
    7. D. Warther,
    8. F. Cunin,
    9. J. O. Durand,
    10. C. J. Drogemuller, et al
    . 2018. Manipulating human dendritic cell phenotype and function with targeted porous silicon nanoparticles. Biomaterials 155: 92–102.
    OpenUrl
  189. ↵
    1. Sehgal, K.,
    2. K. M. Dhodapkar,
    3. M. V. Dhodapkar
    . 2014. Targeting human dendritic cells in situ to improve vaccines. Immunol. Lett. 162(1 Pt A): 59–67.
    OpenUrlCrossRefPubMed
  190. ↵
    1. Thomson, A. W.,
    2. D. M. Metes,
    3. M. B. Ezzelarab,
    4. D. Raïch-Regué
    . 2019. Regulatory dendritic cells for human organ transplantation. Transplant. Rev. (Orlando) 33: 130–136.
    OpenUrl
  191. ↵
    1. Hongo, D.,
    2. X. Tang,
    3. X. Zhang,
    4. E. G. Engleman,
    5. S. Strober
    . 2017. Tolerogenic interactions between CD8+ dendritic cells and NKT cells prevent rejection of bone marrow and organ grafts. Blood 129: 1718–1728.
    OpenUrlAbstract/FREE Full Text
  192. ↵
    1. Luther, C.,
    2. E. Adamopoulou,
    3. C. Stoeckle,
    4. V. Brucklacher-Waldert,
    5. D. Rosenkranz,
    6. L. Stoltze,
    7. S. Lauer,
    8. S. Poeschel,
    9. A. Melms,
    10. E. Tolosa
    . 2009. Prednisolone treatment induces tolerogenic dendritic cells and a regulatory milieu in myasthenia gravis patients. J. Immunol. 183: 841–848.
    OpenUrlAbstract/FREE Full Text
    1. García-González, P. A.,
    2. K. Schinnerling,
    3. A. Sepúlveda-Gutiérrez,
    4. J. Maggi,
    5. L. Hoyos,
    6. R. A. Morales,
    7. A. M. Mehdi,
    8. H. J. Nel,
    9. L. Soto,
    10. B. Pesce, et al
    . 2016. Treatment with dexamethasone and monophosphoryl lipid A removes disease-associated transcriptional signatures in monocyte-derived dendritic cells from rheumatoid arthritis patients and confers tolerogenic features. Front. Immunol. 7: 458.
    OpenUrl
  194. ↵
    1. García-González, P.,
    2. G. Ubilla-Olguín,
    3. D. Catalán,
    4. K. Schinnerling,
    5. J. C. Aguillón
    . 2016. Tolerogenic dendritic cells for reprogramming of lymphocyte responses in autoimmune diseases. Autoimmun. Rev. 15: 1071–1080.
    OpenUrl
  195. ↵
    1. Kryczanowsky, F.,
    2. V. Raker,
    3. E. Graulich,
    4. M. P. Domogalla,
    5. K. Steinbrink
    . 2016. IL-10-modulated human dendritic cells for clinical use: identification of a stable and migratory subset with improved tolerogenic activity. J. Immunol. 197: 3607–3617.
    OpenUrlAbstract/FREE Full Text
  196. ↵
    1. Kim, W. S.,
    2. H. Kim,
    3. K. W. Kwon,
    4. S. H. Im,
    5. B. R. Lee,
    6. S. J. Ha,
    7. S. J. Shin
    . 2016. Cisplatin induces tolerogenic dendritic cells in response to TLR agonists via the abundant production of IL-10, thereby promoting Th2- and Tr1-biased T-cell immunity. Oncotarget 7: 33765–33782.
    OpenUrl
  197. ↵
    1. Wu, A. A.,
    2. V. Drake,
    3. H. S. Huang,
    4. S. Chiu,
    5. L. Zheng
    . 2015. Reprogramming the tumor microenvironment: tumor-induced immunosuppressive factors paralyze T cells. OncoImmunology 4: e1016700.
    1. Jahchan, N. S.,
    2. A. M. Mujal,
    3. J. L. Pollack,
    4. M. Binnewies,
    5. V. Sriram,
    6. L. Reyno,
    7. M. F. Krummel
    . 2019. Tuning the tumor myeloid microenvironment to fight cancer. Front. Immunol. 10: 1611.
    OpenUrl
    1. Harimoto, H.,
    2. M. Shimizu,
    3. Y. Nakagawa,
    4. K. Nakatsuka,
    5. A. Wakabayashi,
    6. C. Sakamoto,
    7. H. Takahashi
    . 2013. Inactivation of tumor-specific CD8+ CTLs by tumor-infiltrating tolerogenic dendritic cells. Immunol. Cell Biol. 91: 545–555.
    OpenUrlCrossRef
    1. Elia, A. R.,
    2. P. Cappello,
    3. M. Puppo,
    4. T. Fraone,
    5. C. Vanni,
    6. A. Eva,
    7. T. Musso,
    8. F. Novelli,
    9. L. Varesio,
    10. M. Giovarelli
    . 2008. Human dendritic cells differentiated in hypoxia down-modulate antigen uptake and change their chemokine expression profile. J. Leukoc. Biol. 84: 1472–1482.
    OpenUrlCrossRefPubMed
    1. Oussa, N. A.,
    2. A. Dahmani,
    3. M. Gomis,
    4. M. Richaud,
    5. E. Andreev,
    6. A. R. Navab-Daneshmand,
    7. J. Taillefer,
    8. C. Carli,
    9. S. Boulet,
    10. L. Sabbagh, et al
    . 2016. VEGF requires the receptor NRP-1 to inhibit lipopolysaccharide-dependent dendritic cell maturation. J. Immunol. 197: 3927–3935.
    OpenUrlAbstract/FREE Full Text
  202. ↵
    1. Oyama, T.,
    2. S. Ran,
    3. T. Ishida,
    4. S. Nadaf,
    5. L. Kerr,
    6. D. P. Carbone,
    7. D. I. Gabrilovich
    . 1998. Vascular endothelial growth factor affects dendritic cell maturation through the inhibition of nuclear factor-kappa B activation in hemopoietic progenitor cells. J. Immunol. 160: 1224–1232.
    OpenUrlAbstract/FREE Full Text
  203. ↵
    1. Wculek, S. K.,
    2. F. J. Cueto,
    3. A. M. Mujal,
    4. I. Melero,
    5. M. F. Krummel,
    6. D. Sancho
    . 2019. Dendritic cells in cancer immunology and immunotherapy. Nat. Rev. Immunol. 20: 7–24.
    OpenUrl
View Abstract
Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools

Jump to section